SYMPHONIX$$$$SUPER NEWS$$$$$ - 500 Beiträge pro Seite

[DOXA DRAMA]

Symphonix` Vibrant(R) Soundbridge(TM) Approved by the Department of Defense
For All Active and Retired Military Personnel

Two Prominent Navy Hospitals in San Diego, Calif. and Portsmouth, Virginia
Have Been Designated to Implant the Hearing Device

SAN JOSE, Calif., Aug. 8 /PRNewswire-FirstCall/ --
Symphonix(R) Devices Inc. (NASDAQ:SMPX) -- developers of the world`s first,
FDA-approved, middle-ear implant for those with moderate to severe
sensorineural hearing loss -- announces that the Department of Defense has
validated treatment and approved coverage for the Vibrant Soundbridge product
for both active and retired military personnel in all branches of the
military.
Currently, otologists and audiologists at two facilities, the San Diego
Naval Medical Center in Southern California and the Medical Center Portsmouth
Naval in Virginia, will perform the procedures and program the devices, with
other facilities to follow. The Medical Center Portsmouth Naval, one of the
country`s first commercial device implanting centers of the Vibrant
Soundbridge, has recently concluded a successful pilot program with the
device, and will build on their experience to offer an expanded practice going
forward.
"The approval by the DoD, spearheaded by the Naval hospital in San Diego,
signals a real commitment by the U.S. government to take care of their
servicemen and women, even years after active duty," said Kirk Davis, chief
executive officer of Symphonix. "Given the rigors of many of their jobs,
current and former military personnel are perhaps the most ideal candidates to
receive the Vibrant Soundbridge implant and enjoy all the benefits it has to
offer."
There are 1.4 million active and over 2.0 million retired military
personnel today. Recent studies conducted by the U.S. Navy Environmental
Health Center indicate that Navy servicemen and women suffer hearing loss at a
rate of double that of the civilian population.
"The DoD acceptance comes on the heels of our launching pilot programs
with the Veterans Administration and Kaiser Hearing Centers of Northern
California," said Terence Griffin, chief financial officer for Symphonix
Devices. "We look forward to continuing our efforts at expanding coverage by
third parties."
Active duty military and retired personnel, as well as dependents, are
eligible for coverage of the procedure commencing with the DoD`s fiscal year
October 1, 2002.
The Vibrant Soundbridge represents a new approach to hearing improvement
-- the implantable middle ear hearing device. Unlike conventional acoustic
hearing aids, which increase the volume of sound that goes to the eardrum, the
Vibrant Soundbridge bypasses the ear canal and eardrum by directly vibrating
the small bones in the middle ear. Because of its design, no portion of the
device is placed in the ear canal itself. The Vibrant Soundbridge has been
approved by the FDA as a safe and effective treatment option for adults with
moderate to severe sensorineural hearing loss who desire an alternative to
acoustic hearing aids.
Individuals with moderate to severe sensorineural hearing loss who are
interested in an alternative to hearing aids, can obtain more information
about the Vibrant Soundbridge middle ear implant by calling Symphonix Devices,
Inc. at 1-800-833-7733, or by visiting the Symphonix Web site at
www.symphonix.com.

About Symphonix Devices, Inc.
Founded in 1994, Symphonix(R) Devices Inc. is a hearing technology company
dedicated to providing a family of products to improve communication ability
and quality of life for the millions of hearing-impaired people limited by
current hearing solutions. Symphonix` Vibrant(R) Soundbridge(TM) is a
surgical implant designed to work with the natural structures of the middle
ear to enhance hearing and communication ability for people with hearing
impairment. The device can be implanted during a short, outpatient medical
procedure. More information about Symphonix can be found at www.symphonix.com
or by calling 800-833-7733.

Statements made in the press release regarding the future performance of
our business, including our marketing and reimbursement initiatives, are
"forward-looking statements" and are subject to a number of uncertainties that
could cause actual results to differ materially from the statements made.
Such risks and uncertainties include, but are not limited to, the Company`s
products failing to achieve widespread market acceptance by otologists,
audiologists and the hearing impaired, including those otologists, audiologist
and hearing impaired in the United States Military. Further information on
potential factors that could affect the Company`s financial results is
included in the Company`s Form 10-Q for the quarter ending March 31 2002, and
Form 10-K for the 2001 fiscal year filed with the Securities and Exchange
Commission.

NOTE: Symphonix and Vibrant are registered trademarks of Symphonix
Devices, Inc. Soundbridge is a trademark of Symphonix Devices, Inc.

Media Contact Investor Relations Contact
Eric Gertsman Terry Griffin
Neale-May & Partners CFO
[phone], ext. 502 Symphonix Devices Inc.
[e-mail] [phone]

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X03007761

SOURCE Symphonix Devices Inc.
-0- 08/08/2002
/CONTACT: Eric Gertsman of Neale-May & Partners, [phone], ext.
502, or [e-mail], for Symphonix Devices Inc.; or Terry Griffin,
CFO of Symphonix Devices Inc., [phone]/
/Web site: http://www.symphonix.com/

[joelu]

kann es sein, daß ich der einzige bin, der nach dieser nachricht gekauft hat. ich depp. in amiland kaum umsatz...und der kurs dümpelt bei 0,47 vor sich hin...

[joelu]

buhuhuhuhuhuhhuuuuuuuuuuu!!!!!!!!!!!


ich bin so alleine in diesem thread. außerdem bin ich der einzige doofe, der gestern gekauft hat, nach der nachricht!!!

[Flickus]

@joelu:
Soooo alleine bist Du gar nicht, ich habs nur bei SMPX fast aufgegeben und sooo doof bist Du auch gar nicht, ich habe die ersten damals bei 9€ !!! eingekauft und dann immer wieder nachgekauft, zuletzt bei 0,8, konnte ja eigentlich nicht mehr tiefer gehen, eigentlich.
Nur wenn die Börse mal wieder kommt und in die andere Richtung übertreibt und dann solche News von SMPX kommen *ja jetzt innerhalb von Monaten schon 2 mal*, dann kanns auch wie damals schlagartig hochrasen. Also Abwarten.
Da steckt langsam alleine bei SMPX en Kleinwagen drin, zum Glück hab ich die Kohle echt über gehabt.
Also Nice weekend

[Viva-los-Tioz]

@joelu

Smphonix mußt Du einfach liegen lassen das ist keine Zocker Aktie wie balsam oder Anza.

Wie Flickus schon sagt,wenn es mal wieder an der Börse Richtung Norden geht dann wird mit Sicherheit Symphonix mehr als überdurchschnitlich profitieren.

Also wenn Du nicht unbedingt die Kohle brauchst die Du in Smpx gesteckt hast,dann warte einfach mal ab und lass die Zeit für Symphonix laufen.

Gruß
Viva

PS: Bin schon über 2 Jahre investiert!

[Flickus]

@Viva-los-Tioz
Häij, dann kennst Du ja auch noch die guten alten Zeiten, wo die SMPX zweimal schlagartig auf 10€ ging, einmal nur, weil sie ihr Patent bekommen haben. Naja, ich denke auch, Schwerhörige gibts genug und SMPX macht ja auch wohl noch andere ganz gute Sachen, vielleicht entwickeln sie ja noch was feines.
Also Abwarten, würd gerne noch nachkaufen, also so richtig, aber eben nix mehr übrig oder was anderes abstoßen, was meinst Du?
Nice weekend

[Viva-los-Tioz]

@Flickus

Ja,die guten alten Zeiten kenne ich natürlich noch!

Nachkaufen würde ich wenn sich Smpx nach einer guten News (wie diese mal wieder)im Kurs etwas beruhigt hat.

Gruß
Viva

[Flickus]

@Viva-los-Tioz
Hab mal in meinen alten Unterlagen gekramt, hihi, hab SMPX in 2000 für 6,3 ge- und bei 7,4 verkauft, Gewinn stolze 400 €. Danach bin ich dann richtig rein und von nun an gings bergab. Heute würd ich bei 6,3 od 7,4 aufm Tisch tanzen, naja mal abwarten.
Hast recht, Nachkaufen besser, wenns sich jetzt erstmal wieder bischen beruhigt hat.
Wünsch Dir ne nordische week :-))

[Viva-los-Tioz]

@Flickus

Hätte damals schon mit ca 70% Gewinn verkaufen können aber habe es nicht getan und danach die ganze Talfahrt mitgemacht.

Aber egal,was zählt ist heute und da bin ich eigentlich wieder Recht Bullish auf SMPX.

Ich werde auf jedenfall meine Anzahl an Shares noch erhöhen.

Gruß
Viva

[joelu]

der kurs kommt langsam wieder. was für ein spread, da wird einem das handelm verlitte. 0,40 -0,76!!!

ist das ding so markteng?

[spekulativ]

@joelu
werde noch den richtigen moment abwarten,und steige dann mal bei euch ein.

Gruß spekulativ

[Viva-los-Tioz]

Hier mal ein paar Infos über Symphonix!


Implantierbares Hörsystem: eine Alternative zum Hörgerät
Den etwa 15 Millionen Schwerhörigen in Deutschland steht jetzt eine Alternative zum konventionellen Hörgerät zur Verfügung: die Vibrant Soundbridge, ein mit modernster digitaler Technik funktionierendes Hörsystem. Das implantierbare System ist besonders interessant für diejenigen, denen aus medizinischen oder kosmetischen Gründen mit normalen Hörgeräten nicht ausreichend geholfen werden kann. Hauptvorteil des neuen Hörsystems ist, dass es ohne zusätzliche operative Maßnahmen den technischen Fortschritten angepasst werden kann. Internationale Erfahrungen mit über 370 schwerhörigen Menschen belegen eine hohe Zufriedenheit mit dem neuen System.


Dank technischer Fortschritte ist die Behandlung von Schwerhörigkeit in den vergangenen Jahren enorm verbessert worden. Moderne Hörcomputer werden in winzig kleine Gehäuse eingebaut, so dass sie beim Tragen fast unsichtbar im Ohr verschwinden. Dennoch eignen sich diese konventionellen Hörgeräte für viele Schwerhörige nicht. Hierzu zählen Menschen mit Kontaktallergien oder einer hohen Produktion von Schweiß oder Ohrenschmalz. Aber auch diejenigen, die eine Blockierung des Ohrkanals (Okklusion) nicht vertragen oder aus kosmetischen Gründen Hörgeräte ablehnen, kommen für die neuen teilimplantierbaren Hörgeräte in Betracht.

Dem Amboss unter die Arme greifen
Die Vibrant Soundbridge besteht aus einem implantierbaren Teil, der VORP (Vibrating Ossicular Prosthesis), und einem außen am Kopf getragenen Teil, dem Audio Processor. Der VORP wurde von der Symphonix Devices, Inc. im Silicon Valley in den USA entwickelt. Es handelt sich um einen Empfänger, der unter der Haut eingepflanzt wird und über einen kleinen Draht mit dem Amboss, einem der drei Gehörknöchelchen, verbunden wird. Am Ende des Drahtes sitzt der sogenannte FMT (Floating Mass Transducer), der halb so groß ist wie ein Reiskorn. Er wandelt die akustischen Signale in mechanische Energie um und gibt diese an die Gehörknöchelchen weiter. So werden ihre natürlichen Bewegungen verstärkt und damit die Hörfähigkeit verbessert.

Der Audio Processor enthält die gleiche Technik wie ein modernes digitales Hörgerät. Fixiert wird er durch einen Magneten am VORP. Er ist etwa so groß wie ein Zwei-Mark-Stück und kann sehr unauffällig unter den Haaren getragen werden. Das hochentwickelte Gerät wird von der Siemens Audiologische Technik hergestellt und arbeitet mit der Signia-ConTrast-Technologie, die kürzlich mit großem Erfolg in einer neuen Generation von Hörcomputern eingeführt wurde.

Wie ein zusätzliches Ohr
Die Soundbridge hat gegenüber vollimplantierbaren Systemen mehrere Vorteile: Sie stimuliert direkt das Mittelohr und lässt dabei den Gehörgang offen und das Trommelfell unbeeinflusst. Signale können damit weiterhin über das Ohr wahrgenommen werden, zusätzlich aber auch über das implantierte Hörsystem. Auf diese Weise wird die Hörqualität maximiert. Die Operation ist im Gegensatz zu Vollimplantierungen reversibel, das heißt, sie kann rückgängig gemacht werden, ohne dass eine Verschlechterung des Gehörs damit verbunden ist. Da der Audio Processor nicht implantiert wird, sondern außen sitzt, ist es möglich, ohne erneute medizinische Eingriffe mit technologischen Fortschritten im Bereich der Signalverarbeitung Schritt zu halten. Auch der Batteriewechsel ist im Vergleich zu vollimplantierbaren Systemen sehr einfach.

Positives Feedback
Weltweit tragen bereits mehr als 370 Menschen die Vibrant Soundbridge - in Deutschland sind es etwa 80 Personen. Klinische Studien in den USA und Europa zeigen gute Ergebnisse hinsichtlich der Verbesserung der Hörfähigkeit. Danach sind etwa 90 Prozent der Träger des neuen Geräts zufrieden bis sehr zufrieden mit der Klangqualität und der Klarheit und Natürlichkeit der Sprache. Rückkoppelungen (Pfeifen) gehören mit diesem System der Vergangenheit an.

Gut geschult
Das Versorgungsnetz ist nach umfassenden Schulungsmaßnahmen bundesweit gut aufgebaut. Neben 14 Kliniken, die den medizinischen Eingriff durchführen können, sind bereits zahlreiche Hörgeräte-Akustiker von der Siemens Audiologische Technik GmbH zertifiziert, den Signia Audio Processor zu programmieren und die Patienten langfristig zu betreuen.

Symphonix Devices AG, Basel, ist die europäische Tochtergesellschaft der Symphonix Devices Inc., San José, USA. Die Firma wurde 1994 mit dem Ziel gegründet, die Vibrant Soundbridge zu entwickeln. Symphonix ist seit 1998 auf dem NASDAQ in New York gelistet (SMPX).

Die Siemens Audiologische Technik GmbH, Erlangen, ist weltweit führend in der Entwicklung und Vermarktung von Hörgeräten und der dazu gehörenden Anpassungssoftware. Sie ist Teil des Siemens-Bereiches Medizinische Technik, einem der größten Anbieter im Gesundheitswesen, der für innovative Produkte, Dienstleistungen und Komplettlösungen steht. Der Bereich Medizinische Technik der Siemens AG erzielte im Geschäftsjahr1998/99 einen Auftragseingang von 4,14 Mrd. Euro (8,1 Mrd. DM) und einen Umsatz von 4,09 Mrd. Euro (8,0 Mrd. DM) und beschäftigt weltweit rund 19.000 Mitarbeiter.

[Viva-los-Tioz]

Siemens festigt strategische Allianz mit Hersteller von Mittelohr-Implantaten durch Kapitalbeteiligung und globaler Marketingzusammenarbeit

Der weltweit führende Hersteller von Hörgeräten, Siemens Audiologische Technik GmbH, Erlangen, ("Siemens") hat eine langfristige strategische Partnerschaft mit Symphonix Devices, Inc. ("Symphonix"), einem Hersteller von Mittelohr-Implantaten mit Sitz in Kalifornien, USA, vereinbart. Ein Aktienkaufvertrag sowie auch eine Marketing- und Vertriebspartnerschaft ergänzen den Technologiekooperations- und Liefervertrag, der am 12. Oktober 1999 von den beiden Unternehmen bekanntgegeben wurde.

"Diese strategische Partnerschaft bringt das in der Hörgerätetechnologie weltweit führende Unter-
nehmen mit einem aufsteigenden Spitzen-
unternehmen für implantierbare Hörgeräte zusammen, zum Nutzen schwerhöriger Patienten weltweit", sagte Hans Mehl, kaufmännischer Geschäfts-
führer der Siemens Audiologische Technik. "Mit den chirurgischen Implantaten von Symphonix sind wir jetzt in der Lage, schwerhörigen Personen, die mit den heutigen In-dem-Ohr- oder Hinter-dem-Ohr-Hörgeräten nicht adäquat versorgt werden können, eine alternative Lösung anzubieten."

Anfängliche Kapitalbeteiligung von US $ 5 Millionen
Im Rahmen des Aktienkaufvertrages hat Siemens eine Million Symphonix-Aktien zu einem Preis von US$ 5 pro Aktie erworben. Außerdem hat sich Siemens bereit erklärt, eine weitere Kapitalbeteiligung in Höhe von US$ 5 Millionen einzugehen, sobald die FDA-Zulassungen für die Soundbridges Vibrant® P und Vibrant® D vorliegen. Siemens hat darüber hinaus das Recht, unter bestimmten Voraussetzungen seine Anteile an Symphonix auf maximal 20 Prozent zu erhöhen.

Infolge der erheblichen finanziellen Beteiligung von Siemens erhält Siemens einen Sitz im Board of Directors von Symphonix, den Hans Mehl einnehmen wird. "Diese Investition unterstreicht unsere Überzeugung, dass Symphonix eine vielversprechende zusätzliche Behandlungsoption für Menschen entwickelt hat, denen mit der traditionellen Hörgerätetechnik nicht geholfen werden kann", merkte Mehl an. "Die Vibrant® Soundbridge hat sich in klinischen Erprobungen in den USA und anderen Ländern gut bewährt, und wir freuen uns infolgedessen, an dieser innovativen Technologie teilzuhaben. Tatsächlich glauben wir, dass wir nun unserer Patientenzielgruppe ein noch vollständigeres Lösungsprogramm anbieten können, da viele Menschen, deren Schwerhörigkeit durch die traditionellen Hörgeräte nicht behandelt werden kann, auf neue Behandlungsformen gewartet haben."

Marketingvereinbarung soll Versorgung Schwerhöriger vorantreiben
Als Teil der Marketing- und Vertriebspartnerschaft hat Siemens die Vertriebsrechte in Europa für einen Zeitraum von zunächst 5 Jahren erworben, wobei Symphonix seine eigene europäische Vertriebsorganisation grundsätzlich beibehält, um Siemens eine umfassende Unterstützung in Vertrieb und Marketing gewähren zu können. Symphonix behält auch seine US-Vertriebsrechte und plant die Vermarktung seiner Produkte nach Erhalt der FDA-Zulassung auf dem Heimatmarkt durch die eigene US-Organisation. Die Vertriebsrechte von Siemens können zukünftig noch auf andere Regionen des Weltmarktes ausgedehnt werden.

Darüber hinaus planen Siemens und Symphonix die Durchführung von gemeinsamen Marketingprogrammen für ihre jeweiligen Produkte in Europa und weiteren Ländern mit dem Ziel der Ermittlung von Patienten, für die die Vibrant® Soundbridge geeignet sein kann. "Siemens wird auf dem audiologischen Sektor hoch geschätzt und hat mit Audiologen weltweit gute Beziehungen entwickelt", kommentierte Kirk Davis, President and Chief Executive Officer (CEO)von Symphonix. "Unsere gemeinsamen Marketinginitiativen zielen darauf ab, diese Beziehungen noch auszubauen, um Symphonix und die Vibrant® Soundbridge einzubeziehen, was uns den potentiellen Zugang zu den Patienten erleichtert, für die unsere Erzeugnisse eine besondere Hilfe sein können."

Über Siemens
Siemens ist einer der weltweit führenden Hersteller von Hörgeräten und der zugehörigen Anpassungs-Software. Seit nahezu 100 Jahren ist das Unternehmen in der Erforschung der Schwerhörigkeit tätig und entwickelt Produkte, die mittlerweile zu Industriestandards für die Unterstützung und Versorgung von schwerhörigen Personen geworden sind.

Über Symphonix
Die 1994 gegründete Firma Symphonix Devices, Inc hat sich der Verbesserung der Kommunikationsfähigkeit und Lebensqualität von Millionen von Schwerhörigen verschrieben hat, denen mit der derzeitigen Hörgerätetechnologie nicht geholfen werden kann. Die Soundbridge Vibrant® von Symphonix ist ein chirurgisches Implantat, das es auf die natürlichen Strukturen des Mittelohrs einwirkt, um die Hör- und Kommunikationsfähigkeit von schwerhörigen Personen zu verbessern. Das Gerät wird in einem chirurgischen Eingriff implantiert. Weltweit wurden Vibrant® Soundbridges bei mehr als 250 Patienten implantiert. Weitere Informationen über Symphonix finden Sie im Internet unter http://www.symphonix.com.

Symphonix und Vibrant® sind eingetragene Warenzeichen von Symphonix Devices, Inc.

[Viva-los-Tioz]

Allianz zum Nutzen hörgeschädigter Patienten

1999 wurde die strategische Allianz zwischen Siemens und Symphonix bekannt gegeben. Mit Siemens als weltweit führendem Hersteller von Hörgeräten und Symphonix als innovativem Unternehmen für implantierbare Hörgeräte kooperieren hier zwei höchst kompetente Partner. Das Ergebnis: Auch Patienten, die mit In-dem-Ohr- oder Hinter-dem-Ohr-Geräten, wie sie derzeit auf dem Markt sind, nicht adäquat behandelt werden konnten, können mit den chirurgischen Implantaten wieder Hoffnung schöpfen. Mittlerweile gibt es in Europa und in den USA viele Hörgeschädigte, die erfolgreich mit dem neuen System behandelt wurden.

Symphonix wurde 1994 in San Jose (Kalifornien) mit dem Ziel gegründet, eine neue Technologie zur Behandlung von Schwerhörigkeit zu entwickeln und zu vertreiben. Floating Mass Transducer (FMT) lautet der Name des neuen Systems. Geoff Ball, Erfinder und Firmengründer ist selbst einer der Patienten, die von der Neuentwicklung profitieren. Symphonix ist ISO-zertifiziert und erhielt 1998 das CE-Zeichen für die Vibrant Soundbridge.

Siemens bringt seine fast 100-jährige Erfahrung in der Erforschung von Schwerhörigkeit in diese Partnerschaft ein. Bei Siemens werden Produkte entwickelt, die mittlerweile als Standards für die Unterstützung und Versorgung von hörgeschädigten Patienten gelten. Aber die Entwicklung steht nicht still: Nicht nur die laufende Optimierung von Hörgeräten und der dazugehörigen Anpassungssoftware gehört zu den Aufgaben der Siemens Audiologische Technik. Immer wieder gilt es auch, neue Wege zu beschreiten - wie bei der Partnerschaft mit Symphonix.

Weitere Informationen über unseren Partner Symphonix finden Sie unter: www.symphonix.com

[Viva-los-Tioz]

Siemens Audiologische Technik GmbH übernimmt Europa-Vertrieb von Symphonix Devices Inc.
Die Siemens Audiologische Technik GmbH, Erlangen, übernimmt zum 1. Januar 2001 den europäischen Vertrieb des Hörsystems Vibrant® Soundbridge von Symphonix Devices Inc., San José, USA. Damit zieht die europäische Vertriebszentrale mit dem kompletten Team der Sales und Marketing Manager sowie Clinical Specialists von Basel nach Erlangen. Symphonix Devices Inc., USA, ist weiterhin für Marketing und Vertrieb in Nordamerika verantwortlich. Die Übernahme der Vertriebsaktivitäten in Europa ist ein weiterer Schritt im Zuge der Kooperation zwischen den beiden Unternehmen, die im Juni 1999 aufgenommen und im November 1999 sowie September 2000 durch eine Minderheitsbeteiligung von Siemens an dem amerikanischen Partner ausgebaut wurde.



Die Vibrant Soundbridge ist eine Alternative für schwerhörige Menschen, denen mit konventionellen Hörgeräten nicht ausreichend geholfen werden kann. Europaweit tragen 350 Patienten das System. 67 Kliniken nehmen hier die Implantation vor. In Deutschland haben bislang Ärzte in 16 Kliniken das System in 87 Patienten implantiert. Die Vibrant Soundbridge erhielt 1998 in Europa das CE-Zeichen. Die amerikanische Gesundheits-behörde FDA erteilte im September 2000 die Zulassung. Der Audio Processor des Hörsystems enthält die digitale Signia-Technologie der Siemens Audiologischen Technik GmbH.

Die heute erhältlichen digitalen Geräte sind weitaus leistungsfähiger, benutzerfreundlicher und selbst als Hinter-dem-Ohr-Geräte so klein, dass sie je nach Geschmack unauffällig oder mit Mut zur Farbe getragen werden können.

Das implantierbare Hörsystem koppelt die Schallschwingen direkt an die Gehörknöchelchen an. Dadurch wird eine Übertragung weiter Frequenzbereiche möglich und gleichzeitig bleibt der Gehörgang offen. Es ergeben sich viele Vorteile für Träger der Vibrant Soundbridge, vor allem was das Sprachverständnis, den natürlicheren Klang der eigenen Sprache und den Tragekomfort angeht. Symphonix Devices Inc., San Jose, USA, wurde 1994 mit dem Ziel gegründet, Produkte für schwerhörige Menschen zu entwickeln, denen mit einer konventionellen Hörgeräte-versorgung nicht ausreichend geholfen werden kann. Das Unternehmen ist seit 1998 auf dem NASDAQ in New York gelistet (SMPX).

Die Siemens Audiologische Technik GmbH, Erlangen, ist weltweit führend in der Entwicklung und Vermarktung von Hörsystemen. Sie ist Teil des Siemens-Bereiches Medizinische Technik, einem der größten Anbieter im Gesundheitswesen, der für innovative Produkte, Dienstleistungen und Komplettlösungen steht. Der Bereich Medizinische Technik der Siemens AG verbuchte im Geschäftsjahr 1999/2000 einen Auftragseingang von 5,3 Mrd. Euro und einen Umsatz von 5,1 Mrd. Euro und beschäftigt weltweit rund 28 000 Mitarbeiter.

[Viva-los-Tioz]

Vibrant Soundbridge
teilimplantiertes Hörsystem
Funktionsweise:

Der Audio Processor ist hinter dem Ohr per Magnet am Kopf befestigt und überträgt das Signal per Funk an den implantierten Empfänger.

Über ein dünnes Leitungskabel wird ein kleiner, am mittleren Gehörknöchelchen befestigter Übertrager, der "FMT", in mechanische Schwingungen versetzt.

Besondere Vorteile:

der externe Soundprocessor kann problemlos ausgetauscht werden, somit können künftige Technologien ohne Operation benutzt werden
keine Rückkopplung durch externe Mikrofonposition

[Viva-los-Tioz]

Vibrant Soundbridge:

Die Vibrant Soundbridge ist das erste chirurgische Implantat, das für die Behandlung eines geringen bis schweren sensorineuralen Hörverlustes (d. h. einer Innenohrschwerhörigkeit) zur Verfügung steht. Die von Symphonix Devices entwickelte Soundbridge (Schallbrücke) funktioniert im Mittelohr. Das Gerät simuliert und verstärkt die natürlichen Bewegungen der vibrierenden Gehörknöchelchen und verbessert dadurch die Qualität der Tonsignale, die das Innenohr und von dort aus das Gehirn erreichen.


Bei der Verwendung der Soundbridge bleibt der Gehörgang offen, es treten weder Okklusionen noch Druckempfindungen auf, und die örtliche Bestimmung des Schalls wird verbessert. Akustische Rückkopplung, über die sich Hörgeräteträger häufig beschweren, tritt nicht auf. Die Soundbridge ist so konzipiert, daß sie die Sprachgenauigkeit (natürlicher Ton) und die Sprachverständlichkeit verbessert. Die bei sichtbaren Hörgeräten auftretenden ästhetischen Probleme werden vermieden, da das Haar des Trägers in der Regel den äußerlich getragenen Audio Processor verdeckt. Diese Eigenschaften bewirken für den Hörbehinderten Verbesserungen in psychologischer wie in beruflicher Hinsicht, was eine höhere Lebensqualität zur Folge hat.

Die Vibrant Soundbridge besteht aus zwei Teilen: 1) dem Implantat, das als Vibrating Ossicular Prosthesis (VORP) bezeichnet wird, und 2) dem äußerlich getragenen Audio Processor. Das VORP wird durch einen chirurgischen Eingriff implantiert. Es besteht aus dem Floating Mass Transducer (FMT), einem Leitungskabel und einem internen Empfänger. Der FMT wird am Amboß im Ohr des Patienten befestigt.

Nach der Genesung des Patienten von dem chirurgischen Eingriff wird der Audio Processor an dessen Kopf angebracht. Er enthält ein Mikrophon, programmierbare Verarbeitungselektronik, ein Übertragungssystem und eine Batterie für die Energieversorgung. Der Audio Processor wird mit einem Magneten hinter dem Ohr des Patienten festgehalten. Der Audio Processor wird durch uns angepaßt, um die optimale Sprachverständlichkeit zu erreichen.

[Viva-los-Tioz]

[Flickus]

@Viva-los-Tioz:
Was glaubst Du denn, wie`s mit unserer SMPX weitergeht??
Noch ein bisserle nachkaufen oder einfach mal abwarten?
Gruß
Flickus

[Viva-los-Tioz]

@Flickus

Gute Frage,darauf die richtige Antwort zu finden ist schon schwer.

Ich denke das es demnächst mal wieder richtig noch oben geht(gute News) aber ob bis dahin noch der Kurs ein wenig nachgibt weiß ich auch nicht.

Gruß
Viva

[Viva-los-Tioz]

Diese Kongresse und Informationsveranstaltungen könnten sehr interessant für Symphonix werden.

Gruß
Viva


4.-6.9.2002 Manchester
7th International Cochlear Implant Conference 2002
Information:
Manchester Conference Centre, UMIST, Trading Services, PO Box 88, Sackville Street, Manchester M6O 1QD, UK, Tel.: [phone], Fax: [phone]

6.-7.9.2002 Leipzig
11.Jahrestagung der Vereinigung Mitteldeutscher HNO-Ärzte
Information:
Prof.Dr.F.Bootz, Universitäts-HNO-Klinik, Liebigstrasse 18 a, D-04103 Leipzig,
Deutschland, Tel.: [phone], Fax: [phone]

8.-10.9.2002
International Training Course on Endoscopic an Microscopic Sinus Surgery
Surgery Course with with Practical Exercises: 11.-13.09.2002
Information:
S. Zapf, Sekretariat Prof. Werner, Klinik für HNO-Heilkunde, Univ. Marburg,
Deutschhausstr. 3, 35037 Marburg, Tel: [phone], Fax: [phone],
E-Mail: [e-mail], www.hno-marburg.de />
11.-14.9.2002 - Oxford / Großbritannien (Great Britain)
8th International Congress on Paediatric Otorhinolaryngology
Information:
Concorde, 42 Canham Road, London W3 7SR, Tel.: [phone], Fax: -/87431010,
[e-mail], http://www.concorde-uk.com, http://www.espo-euro.org

13.-14.9.2002 – Karlsruhe
Audiometriekurs für HNO-Ärzte
Information:
Audiologie, Ltr. Dipl. Phys. U. Pieper, Tel. [phone], Fax [phone]

18.-21.9.2002 - San Diego / USA / CA
Fall Meeting of the American Academy of Facial Plastic and Reconstructive Surgery
Information:
L.Hacek, American Acad.of Facial Plastic & Reconstructive Surgery, 310 S.Henry Street, USA - Alexandria, VA 22314, Tel.: [phone], Fax: -/299-8898,
[e-mail], http://www.aafprs.org />
18.-21.9.2002 - Feldkirch / Österreich (Austria)
Montforthaus
46.Österreichischer HNO-Kongress
Information:
LKH Feldkirch, Prim.Dr.Herbert Siegl, A-6800 Feldkirch, Tel.: [phone],
Fax: -/303

19.-21.9.2002 - Magdeburg
Univ.-HNO-Klinik
Operationskurs - Plastisch-rekonstruktive Chirurgie im Kopf-Hals-Bereich
Information:
Otto-von-Guericke-Universität, Univ.-HNO-Klinik, Leipziger Straße 44, 39120 Magdeburg, Tel.: [phone], Fax [phone], Sekretariat Frau Malzahn

21.9.2002 - Bad Arolsen
Twisteseehalle Wetterburg
7.Bad Arolser Tinnitus-Symposium
Information:
Tinnitus-Klinik, Europ.Akademie für Retraining- und Hörtherapie, Große Allee 3, D-34454 Bad Arolsen, Tel.: [phone], Fax: -/896700, http://www.tinnitus-klinik.de />
22.-25.9.2002 - Orlando / USA / FL
106th Annual Meeting of the American Academy of Otolaryngology Head
and Neck Surgery
Information:
J.Hayes, AAD-HNS, One Prince St., USA-Alexandria, VA 22314,
Tel.: [phone], Fax: -/519-1546

22.-25.9.2002 - San Diego / USA / CA
Annual Meeting of the American Academy of Otolaryngology Head and Neck Surgery
Information:
J.Hayes, AAD-HNS, One Prince St., USA-Alexandria, VA 22314, Tel.: [phone], Fax: /519-1546, [e-mail], http://www.entnet.org


26.-28.9.2002 - Hannover
Medizinische Hochschule Hannover
Kongress Neugeborenen-Hörscreening mit Workshop
Information:
Gabi Richardson, Klinik und Poliklinik für HNO-Heilkunde, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Tel.: [phone], Fax: [phone]

26.-29.9.2002 – Berlin
ICC
100.Tagung der Deutschen Ophthalmologischen Gesellschaft – DOG
Information:
Dt.Ophthalmolog.Ges., Berliner Straße 14, D-69120 Heidelberg, Tel.: [phone], Fax: -/484616, [e-mail], http://www.dog.org

27.-28.9.2002 - Mainz
Kurfürstl.Schloß
86.Jahrestagung der Vereinigung Südwestdeutscher HNO-Ärzte
Information:
Vereinig.Südwestdt.HNO-Ärzte, Prof.Dr.J.Maurer, Univ.-HNO-Klinik, Langenbeckstr.1,
D-55101 Mainz, Tel.: [phone], Fax: -/176637, Fr.C.Broo


28.-30.9.2002 - Paris / Frankreich (France)
Oto-Neurosurgery Course - Organized by the Societe d´otologie pratique
Information:
Dr.A.A.Sultan, Société D`Otologie Pratique, 23, rue Cauchaix, F-95170 Deuil la Barre, Tel.: [phone], Fax: -/49400643, [e-mail]

[Flickus]

Hallo Leute, weiß einer warum die SMPX heute über 10 % zulegt? Von mir aus kann das so weitergehen, langsam aber stetig immer mal plus 10 oder mehr % :-))
Nice weekend an alle SMPX`ler

[Viva-los-Tioz]

@Flickus

Langsam gen Norden genau darauf hoffe ich bevor dann einige sehr gute News kommen.

Gruß
Viva

[Flickus]

@Viva-los-Tioz

Ja das hoffe ich auch, so schön langsam bis 0,8 *da bin ich nämlich damals wieder rein*, daß die Börsenstimmung sich weiter so aufhellt *alles schön langsam und bedächtig*, daß die Amis im Irak keinen Mist machen *dann rast bestimmt erst mal alles wieder Richtung Süden* UND dann suuuper News von SMPX, und ab Richtung Norden vielleicht sogar bis auf 3 - 4 € *oder ist das zu vermessen?*
Nice weekend
Flickus

[Viva-los-Tioz]

Hallo Flickus,

genau so soll es kommen langsam auf die 0,80 und dann auf 3-4 Dollar.

Wenn die News so gut werden wie ich es vermute,dann glaube ich auf langer Sicht sogar wieder an die 10 Dollar und mehr.


Wünsche Dir und allen anderen Investierten noch ein schönes Wochenende.

Gruß
Viva

[Flickus]

Hallo Viva-los-Tioz,
also wenn Du mit 10 Dollar recht hast *natürlich noch vor dem nächsten Jahrzehnt :-))* dann geb ich dir nen Chamus aus, --really--
und ich kauf noch schnell nach *lach*
Aber denkbar ist das schon, weil dieses Produkt SO ja einzigartig ist.
Hast Du denn schon was konkreteres, was da so an guten news von SMPX kommen könnte??
Bis dahin
Gruß Flickus

[Viva-los-Tioz]

Hi Flickus,

ich freue mich schon auf den Champus,grins.

Ich denke da kommen einige gute News in den nächsten Monaten,eine ganz wichtige wird aus Frankreich kommen.

Gruß
Viva

[Viva-los-Tioz]

Hallo Flickus,

hast Du dir am Freitag noch einmal 800 Stk. eingetütet?


Gruß und einen schönen Sonntag wünscht Dir

Viva

[Flickus]

@Viva-los-Tioz
Ne, war ich nicht, bin im Depot momentan auch nicht cash, müßte also was anderes dafür verkaufen und da würd ich auch grad jetzt erstmal bischen abwarten, obwohl, der Preis ist ja schon verlockent, vor allem hält sich die SMPX doch beachtlich um die 0,5, naja mal abwarten.
Have a nice start into the next week
Flickus

[Viva-los-Tioz]

Hallo,

Symphonix liegt stabil um die 45 cent und man kann darauf Wetten das bei den nächsten guten News der Kurs durch die Decke gehen wird.

Die Umsätze in Deutschland werden dann auch wieder kommen.

Wünsche allen investierten (besonders Flickus) ein schönes Wochenende.


Gruß
Viva

[Viva-los-Tioz]

News!
--------------------------------------------------------------------------------
Symphonix(R) Devices Features Its Vibrant(R) Soundbridge(R) Technology at Major Trade Meeting Booth Highlights and Sponsorships Mark the Company`s Presence at The American Academy of Otolaryngology Annual Meeting


SAN DIEGO, Sep 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- Symphonix(R)
Devices Inc. (Nasdaq: SMPX) -- developers of the world`s first, FDA-approved,
middle-ear implant for those with moderate to severe sensorineural hearing loss
is showcasing its Vibrant(R) Soundbridge(R) product at The 106th American
Academy of Otolaryngology Annual Meeting, September 22-25 at Booth 1839 within
the San Diego Convention Center.

Symphonix is highlighting a variety of interesting features at their exhibition
booth. First, as a part of a concerted effort to educate the otolaryngology
community and the general population about the increase in insurance
reimbursement rates for the Vibrant Soundbridge device and procedure, Symphonix
has set aside a section of their booth to provide comprehensive insurance
information to attendees. Representatives and literature are available to answer
questions. "We feel it is a crucial time for otolaryngologists and other
professionals in the trade to begin understanding how insurance companies are
dealing with the Vibrant Soundbridge and the success we have had working with
them," said Kirk Davis, chief executive officer of Symphonix.

In addition, Symphonix is displaying the Direct Drive Simulator units, which are
used to give patients sound demonstrations of the Vibrant Soundbridge technology
prior to any surgical procedures. Such previews are rare with surgically
implanted medical devices and thus, the units mark an innovative step in
increasing patient confidence and comfort level. In limited preliminary
distribution, Symphonix has had good success with otologist adoption of the
units and now looks to roll them out on a broader basis.

Also at the booth is a model of the inside of the human ear fitted with an
implanted Vibrant Soundbridge device. With a microscope, attendees have the
opportunity to view the anatomical structures involved in the implant procedure
and get a sense of how the Floating Mass Transducer(TM) clips to the incus bone.

Accompanying the other booth features are Vibrant Soundbridge users to explain
their experiences with the improved sound quality they have gained from the
device.

On Saturday, September 21, Symphonix co-sponsored the American Neurotology
Society Fall Scientific Program, which was also held in San Diego. In addition
to financial support for the program, they provided key data for the
presentation given by Dr. Peter Weber of the Cleveland Clinic. Dr. Weber`s
lecture titled, "Reimbursement Issues Related to Implantable Hearing Devices,"
discussed points such as the recent insurance progresses made by implanted
hearing devices, coding and diagnosis options for doctors, and a discussion of
medical necessities appropriate to Vibrant Soundbridge therapy.

This morning, Symphonix also co-sponsored the Annual Meeting of the Society of
Military Otolaryngologists. The event was attended by Retired Rear Admiral Allen
E. Hill, a Vibrant Soundbridge user. Symphonix has been increasing their
military-related activities since the Department of Defense recently approved
insurance coverage of the Vibrant Soundbridge for active and retired military
personnel.

The Vibrant Soundbridge represents a new approach to hearing improvement: the
implantable middle ear hearing device. Unlike conventional acoustic hearing
aids, which increase the volume of sound that goes to the eardrum, the Vibrant
Soundbridge bypasses the ear canal and eardrum by directly vibrating the small
bones in the middle ear. Because of its design, no portion of the device is
placed in the ear canal itself. The Vibrant Soundbridge has been approved by the
FDA as a safe and effective treatment option for adults with moderate to severe
sensorineural hearing loss who desire an alternative to acoustic hearing aids.

Individuals with moderate to severe sensorineural hearing loss who are
interested in an alternative to hearing aids, or otolaryngologists who would
like to learn more about the Vibrant Soundbridge middle ear implant, can obtain
more information by calling Symphonix Devices, Inc. at 1-800-833-7733, or by
visiting the Symphonix Web site at www.symphonix.com.

About Symphonix Devices, Inc.

Founded in 1994, Symphonix(R) Devices Inc. is a hearing technology company
dedicated to providing a family of products to improve communication ability and
quality of life for the millions of hearing-impaired people limited by current
hearing solutions. Symphonix` Vibrant(R) Soundbridge(TM) is a surgical implant
designed to work with the natural structures of the middle ear to enhance
hearing and communication ability for people with hearing impairment. The device
can be implanted during a short, outpatient medical procedure. More information
about Symphonix can be found at www.symphonix.com or by calling 800-833-7733.

Statements made in the press release regarding the future performance of our
business, including our marketing initiatives, are "forward-looking statements"
and are subject to a number of uncertainties that could cause actual results to
differ materially from the statements made. Such risks and uncertainties
include, but are not limited to, the Company`s products failing to achieve
widespread market acceptance by otologists, audiologists and the hearing
impaired, and the Company`s products not being reimbursed by insurance
companies. Further information on potential factors that could affect the
Company`s financial results is included in the Company`s Form 10-Q for the
quarter ending June 30 2002, and Form 10-K for the 2001 fiscal year filed with
the Securities and Exchange Commission.

NOTE: Symphonix and Vibrant are registered trademarks of Symphonix Devices, Inc.
Soundbridge is a trademark of Symphonix Devices Inc.



MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X87551263

SOURCE Symphonix Devices Inc.



CONTACT: media, Eric Gertsman of Neale-May, [phone], ext. 148,

or [e-mail], for Symphonix Devices Inc.; or investors,

Terry Griffin of Symphonix Devices Inc., [phone], or

[e-mail]



URL: http://www.symphonix.com

http://www.prnewswire.com


Copyright (C) 2002 PR Newswire. All rights reserved.





KEYWORD: California

INDUSTRY KEYWORD: MTC

HEA

SUBJECT CODE: TDS

[Flickus]

@Viva-los-Tioz
Danke für das schöne weekend, na war auch nicht schlecht.
Letzte Woche habe auch ich bei nem Amiwert mal hautnah miterlebt, wie die Shares aufgrund von ner Pleite plötzlich nur noch Cents wert sind, hihi. Also eigentlich nicht hihi :-( Also muß es die SMPX nu richten, wenn sie im Dezember noch so billig ist, dann tüte ich tatsächlich nochmals einige ein, weiß noch nicht, was meinst Du, so 1000 Stückerle müßten doch noch mal zu setzen sein??
Nice week
Flickus

[Viva-los-Tioz]

Hallo Flickus,

also wenn Smphonix im Dezember noch so günsig zu haben sind werde ich mir auf alle Fälle noch einige ins Depot legen.

Wünsche Dir auch eine erfolgreiche schöne Woche


Gruß
Viva

[WildZeitung]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Viva-los-Tioz]

Hallo Se...,


schön das Du noch dabei bist.
Das Du gesperrt warst zeigt doch mal wieder das man in Deutschland meist nur das sagen darf was andere gerne hören möchten.

Die Wahrheit wird oft bestraft!

Ich glaube wie Du sicherlich schon bemerkt hast ganz fest an Symphonix und hoffe das in den nächsten Wochen noch ein paar gute News kommen.


Gruß
Viva

[Flickus]

@Viva-los-Tioz
Schade, nu bröckelt die SMPX doch leider nach und nach und nach und...
Wird wohl an der Gesamtlage der Börsen liegen, ist ja echt bald nicht mehr mit anzuschauen. Na wird wohl innerhalb der nächsten 25 Jahre mal wieder besser *lach*
Ich bin ab Sonntag nu erstmal 4 Wöchelchen in Malaysia, mal sehen was die Shares dort so machen.
Gruß
Flickus

[Viva-los-Tioz]

Hallo Flickus,

ist echt eine Schande was an der Börse so abgeht.Werde trotz allen im Dezember noch einmal kräftig nach kaufen,hätte gerne dann den Kurs den der Stuttgarter Makler heute gestellt hat.

Wünsche Dir eine schöne Zeit in Malaysia und komm gesund zurück.

Gruß
Viva

[Flickus]

Hai Viva-los-Tioz,
werd vermutlich im Dezember auch noch SMPX und nen anderen Wert bischen nachkaufen.
Ansonsten meld ich mich mal aus nem Cybercafe, wenn Du ne total verschwitzte Nachricht liest, hihi, dann ist sie von mir aus Malaysia.
Bis dahin Dir auch alles Gute
Flickus

[Viva-los-Tioz]

Wo ist denn das Posting von Searg geblieben,ist der schon wieder gesperrt worden? Und wurden alle seine Postings dadurch gelöscht?

[Viva-los-Tioz]

Schon wieder geperrt!Mensch was hast Du denn jetzt schon wieder verbrochen?



Username: WildZeitung gesperrt
Registriert seit: 24.09.2002
User ist momentan: Offline
Letztes Login: 28.09.2002 21:14:29
Threads: 2
Postings: 5
Interessen keine Angaben

[Viva-los-Tioz]

Hallo zusammen,

im Moment ist ja nicht viel los mit Symphonix.

Hoffe das ich Anfang Dezember noch so günstige Kurse zum nachkaufen bekomme.

Gruß
Viva
@ Flickus Ich hoffe Du läßt es Dir gut gehen.

[Flickus]

@ Viva-los-Tioz:
Klar lasse ichs mir hier unten gut gehen, ist nur sooo schwuelheiss, ist echt unglaublich und nachts nicht ein Gramm kuehler. Na das wird sich ja naechste week fuer mich schlagartig aendern, hihi, soll ja bei euch recht kuehl sein.
Hab heute mal in mein depot geschaut, smile, so koennte es die naechsten 12 Monate weiter gehen, ab Dez. dann noch die SMPX, wenn wir beide nachgekauft haben.
Bis daenne, hast Du noch mal was neues ueber SMPX rausbekommen?? Haengt Siemens da noch mit drin, hab bislang nichts anderes gehoert, dann muesste es ja eigentlich mal wieder Richtung Norden gehen.
Flickus

[Viva-los-Tioz]

Hallo Flickus,

schön das es Dir gut geht! Genisse die letzten schönen Tage,denn hier ist das Wetter mal wieder Typisch Deutsch (Regen um die 15C°).

Siemens ist natürlich noch dabei und die Wissen auch warum Neuigkeiten gibt es i.M. nicht und das der Kurs Richtung Norden geht ist uns beiden ja längst bekannt.

Ich Wünsche Dir noch einen schönen Urlaub und komm Gesund wieder.

Bis dann

Viva

[Viva-los-Tioz]

Symphonix Devices Inc. Announces Q3 2002 Financial Results

SAN JOSE, Calif., Oct 24, 2002 /PRNewswire-FirstCall via COMTEX/ --
Symphonix(R) Devices Inc. (Nasdaq: SMPX) -- developers of the world`s first
FDA-approved middle-ear implant for moderate to severe sensorineural hearing
loss -- today reported a net loss of $1.9 million, or $0.05 per share, for the
third quarter ended September 30, 2002, compared to $1.8 million, or $0.05 per
share, for the second quarter of 2002 and $3.8 million, or $0.11 per share, for
the third quarter of 2001.

Net loss for the nine months ended September 30, 2002 was $5.7 million, or $0.16
per share, compared to $13.7 million, or $0.54 per share, for the nine months
ended September 30, 2001. Revenue for the quarter was $0.4 million compared to
$0.5 million for the third quarter of 2001. Revenue for the nine months ended
September 30, 2002 was $1.4 million compared to $1.5 million for the nine months
ended September 30, 2001.

CEO Kirk Davis stated that several business and marketing initiatives are
underway to increase product adoption by audiologists, the key patient referral
source for the Vibrant(R) Soundbridge(R) technology.

"We have been introducing new programs and expanding others in a concerted
effort to address the key issues with regard to adoption of this new technology
for moderate to severe sensorineural hearing loss," stated Davis, "and Q3 marked
a time of progress toward achieving these goals."



Highlights of marketing successes in the third quarter include:



-- In an effort to simultaneously increase patient confidence and provide

audiologists with a personal "test drive" of the technology, Symphonix

introduced the Direct Drive Simulator -- a demonstration system that

allows patients to personally experience the benefits of the company`s

Vibrant Soundbridge implantable middle-ear hearing device before

surgery. After a successful beta test, the Direct Drive Simulator units

have just recently been widely distributed to otologist clinics

worldwide, further reinforcing the audiologist to otologist referral

relationship.

-- In support of the company`s continuing efforts to reinforce the safety

and effectiveness of the Vibrant Soundbridge technology, findings from

a long-term patient study were recently released. The findings by the

clinical investigators concluded that patients implanted with the

Vibrant Soundbridge technology over a five-year period found that it is

not only safe and effective long after initial activation, but also

reaffirmed the original, outstanding clinical trial results.

-- The company continues to gain acknowledgement by health insurance

companies for the benefits the Vibrant Soundbridge brings to their

members. Based on this momentum, the company has introduced an

insurance guarantee program in selected markets designed to increase

adoption by audiologists by removing the issue of price from the

patient`s decision-making process. With the ultimate goal to provide

the audiologist with a successful Vibrant Soundbridge patient referral,

Symphonix will help facilitate and streamline the process for patients

seeking insurance coverage.

Another key business objective is securing widespread adoption of the Vibrant
Soundbridge technology throughout the U.S. military. After a successful pilot
program and upon gaining reimbursement from the military effective October 1,
2002, the company is focusing on rolling out the Vibrant Soundbridge to military
hospitals that have otologists on staff. The company expects to see revenue
growth from this program in 2003.

In addition, Symphonix recently launched a pilot program with the Veterans
Administration (VA), where the first VA surgery of the Vibrant Soundbridge was
conducted at the VA Hospital in San Francisco, California, on September 17,
2002. The Veterans Administration represents ten percent of the total U.S.
hearing healthcare market, and the company expects additional surgeries to be
scheduled in the coming months as part of its planned expansion of the pilot
program within the Veterans Administration.

The Vibrant Soundbridge represents an innovative approach to hearing improvement
-- the first implantable middle ear hearing device. Unlike conventional acoustic
hearing aids, which increase the volume of sound that goes to the eardrum, the
Vibrant Soundbridge bypasses the ear canal and eardrum by directly vibrating the
small bones in the middle ear. Because of its design, no portion of the device
is placed in the ear canal itself. The Vibrant Soundbridge has been approved by
the FDA as a safe and effective treatment option for adults with moderate to
severe sensorineural hearing loss who desire an alternative to acoustic hearing
aids. Of the approximate 28 million Americans who suffer from hearing loss, 60
percent have moderate to severe hearing loss.

About Symphonix Devices, Inc.

Founded in 1994, Symphonix Devices Inc., is a hearing technology company
dedicated to providing a family of products to improve communication ability and
quality of life for the millions of hearing-impaired people limited by current
hearing solutions. Symphonix` Vibrant Soundbridge is a surgical implant designed
to work with the natural structures of the middle-ear to enhance hearing and
communication ability for people with hearing impairment. The device can be
implanted during a short, outpatient medical procedure. More information about
Symphonix Devices, Inc. can be found at www.symphonix.com or by calling
800-833-7733.

Statements made in the press release regarding the future performance of our
business, including our marketing initiatives, are "forward-looking statements"
and are subject to a number of uncertainties that could cause actual results to
differ materially from the statements made. Such risks and uncertainties
include, but are not limited to, the Company`s products failing to achieve
widespread market acceptance by otologists, audiologists and the hearing
impaired, including those in the military and Veterans Administration, and the
company`s products failing to obtain insurance reimbursement. Further
information on potential factors that could affect the Company`s financial
results is included in the Company`s Form 10-Q for the quarter ending June 30
2002, and Form 10-K for the 2001 fiscal year filed with the Securities and
Exchange Commission.

NOTE: Symphonix, Vibrant and Soundbridge are registered trademarks of Symphonix
Devices, Inc.



Summary Consolidated Financial Information

(Thousands, except per share amounts)



Statement of Operations Data

(Unaudited)



Quarter ended Nine months ended

September 30, September 30,

2002 2001 2002 2001





Revenue $404 $535 $1,397 $1,546



Expenses:

Cost of goods sold 420 1,342 1,289 3,665

Research & development 526 1,406 1,904 4,927

Selling, general

& administrative 1,365 1,817 4,337 7,318

Total costs and expenses 2,311 4,565 7,530 15,910

Operating loss (1,907) (4,030) (6,133) (14,364)

Interest income, net 31 242 384 656

Net loss $(1,876) $(3,788) $(5,749) $(13,708)



Basic and diluted

net loss per

common share $(0.05) $(0.11) $(0.16) $(0.54)



Number of shares used

in calculation of basic

and diluted net loss

per common share 35,803 33,399 35,710 25,190







Balance Sheet Data



September 30, December 31,

2002 2001

(Unaudited)



Cash and cash

equivalents,

restricted cash

and short-term

investments $4,581 $12,291

Total assets 6,843 15,155

Stockholders` equity 3,348 9,288





Make Your Opinion Count - Click Here

http://tbutton.prnewswire.com/prn/11690X24663767

SOURCE Symphonix Devices Inc.



CONTACT: media, Denise Apcar of Neale-May & Partners, [phone],

ext. 514, or [e-mail]; or investors, Terry Griffin, CFO of

Symphonix Devices Inc., [phone]



URL: http://www.symphonix.com

http://www.prnewswire.com


Copyright (C) 2002 PR Newswire. All rights reserved.





KEYWORD: California

INDUSTRY KEYWORD: HEA

MTC

BIO

FIN

SUBJECT CODE: ERN

[Viva-los-Tioz]

Letzte Nachrichten

Symphonix Geräte Inc. gibt Q3 2002 finanzielle Ergebnisse bekannt
San JOSE, Calif, 24. Okt 2002 /PRNewswire-FirstCall über COMTEX/--
Symphonix (R) Geräte Inc. (Nasdaq: ) - Entwickler von der ersten der Welt
FDA genehmigtes mittleres Ohrenimplantat für Gemäßigten zu schwerwiegender sensorineural Anhörung
Verlust - heute berichtete über einen Nettoverlust an $ 1,9 Millionen oder $ 0,05 pro Aktie für d
drittes Viertel beendete September 30, 2002, mit $ 1,8 Millionen oder $ 0,05 verglichen pro
teilen Sie für das zweite Viertel der 2002 und $ 3,8 Millionen oder $ 0,11 pro Aktie für
das dritte Quartal von 2001.

Nettoverlust für die neun September 30, 2002, beendeten Monate war $ 5,7 Millionen oder $ 0,16
pro die neun Monate mit $ 13,7 Millionen oder $ 0,54 pro Aktie verglichene Aktie
beendeten 30. September 2001.
Erlös für das Viertel war verglichen $ 0,4 Millionen zu
$ 0,5 Millionen für das dritte Quartal von 2001.
Erlös für die neun Monate endete
Am 30. September war 2002 mit $ 1,5 Millionen die neun Monate verglichen $ 1,4 Millionen
beendeten 30. September 2001.

Vorstandsvorsitzendenkirche Davis gab an, daß mehrere Geschäfts- und Marketinginitiativen sind
im Gang um Produktannahme audiologists, den Schlüsselpatienten referral zu steigern
Quelle für die vibrierende (R) Soundbridge (R) Technologie.

"Wir haben neue Programme eingeführt und andere ausgedehnt in ein abgestimmt
Anstrengung, die Hauptprobleme mit Rücksicht auf Annahme dieser neuen Technologie anzusprechen
für Gemäßigten zu schwerwiegendem sensorineural Anhörungsverlust, "gab Davis an,", und Q3 markierte
eine Zeit des Fortschritts, in Richtung diese Ziele zu erreichen, ".




Höhepunkte, Erfolge beim dritten Viertel zu vermarkten, beinhalten:




- in einer Anstrengung, simultan geduldiges Vertrauen zu steigern und zu liefern

audiologists mit einer persönlichen "Probefahrt" von der Technologie, Symphonix

führte den direkten Elansimulator ein - ein Vorführungssystem das

erlaubt Patienten, die Nutzen des Unternehmens persönlich zu erfahren

Vibrierendes Soundbridge implantierbares mittleres Ohr, das zuvor Gerät hört

eine Operation.
Nach einem erfolgreichen Betatest, den direkten Elansimulatoreneinheiten

seien Sie gerade vor kurzem häufig an otologist Kliniken verteilt worden

fördern Sie weltweit, das audiologist zu otologist referral zu verstärken

Verbindung.

- in Betreuung von den kontinuierlichen Versuchen des Unternehmens, die Sicherheit zu verstärken

und Wirksamkeit vom vibrierender Soundbridge Technologie, Befunden von

eine langfristige geduldige Studie wurde vor kurzem herausgegeben.
Die Befunde von d

klinische Ermittler schlossen, daß Patienten implantierten mit, d

Vibrierende Soundbridge Technologie in einer Fünfjahresperiode fand, daß sie ist

nicht nur sicherer und wirksamer Langläufer nach Anfangsaktivierung, aber auch

beteuerte die Original-, offenen klinischen Versuchsergebnisse.

- das Unternehmen fährt fort, Bestätigung durch Krankenversicherung zu gewinnen

Unternehmen für die Nutzen das vibrierende Soundbridge bringt ihr

Mitglieder.
Auf Grundlage von diesem Schwung hat das Unternehmen eingeführt ein

Versicherungsgarantieprogramm auf gewählten Märkten, die dafür entworfen sind zuzunehmen

Annahme audiologists durch Entfernen der Angelegenheit des Preises von d

der Entscheidungsfindungsprozeß des Patienten.
Mit dem endgültig zu liefernden Ziel

das audiologist mit einem erfolgreichen vibrierenden Soundbridge geduldigen referral

Symphonix hilft zu erleichtern für Patienten und rationalisiert für sie den Prozeß

das Suchen der Versicherungsdeckung.

Ein anderes Schlüsselgeschäftsziel sichert verbreitete Annahme der vibrierenden
Soundbridge Technologie überall in dem US-Militär.
Nach einem erfolgreichen Piloten
programmieren und beim Gewinnen der Erstattung vom Militär am wirksamen 1. Oktober
2002, das Unternehmen zielt darauf, aus das vibrierende Soundbridge zu Militär zu rollen
Krankenhäuser, die otologists weiter haben, besetzen mit Personal.
Es erwartet, daß das Unternehmen Erlös sieht
Wachstum von diesem Programm an 2003.

Außerdem führte Symphonix vor kurzem ein Pilotprogramm mit den Veteranen ein
Verwaltung (VA), wo die erste VA Operation am vibrierenden Soundbridge war
geführt im VA Krankenhaus in San Francisco, Kalifornien am 17. September
2002.
Die Veteranen Verwaltung stellt zehn Prozent der totalen USA dar
healthcare Markt und das Unternehmen zu hören, erwartet, daß zusätzliche Chirurgien sind
festgesetzt in den kommenden Monaten als Teil seiner geplanten Erweiterung des Piloten
programmieren Sie innerhalb der Veteranen Verwaltung.

Das vibrierende Soundbridge stellt einen innovativen Ansatz zu Anhörungsverbesserung dar
- das erste implantierbare Mittelohranhörungsgerät.
Unähnlich konventionell akustisch
Hilfen hören, die das Volumen des Geräusches steigern, das zum eardrum geht, d
Vibrierendes Soundbridge umgeht den Ohrenkanal und das eardrum durch direktes Vibrieren d
Kleiner entbeint im Mittelohr.
Wegen seines Entwurfs, keines Teils des Geräts
wird in den Ohrenkanal selbst gestellt.
Das vibrierende Soundbridge ist genehmigt worden
das FDA als eine sichere und wirksame Behandlungsauswahlposition für Erwachsene mit Gemäßigtem zu
schwerwiegender sensorineural Anhörungsverlust wer wünschen eine Alternative zu akustischer Anhörung
Hilfen.
Von den ungefähren 28 Millionen Amerikanern, die daran leiden, Verlust, 60, zu hören
Prozent haben Gemäßigten zu schwerwiegendem Anhörungsverlust.

Über Symphonix Geräte, Inc.

Gründete in 1994, Symphonix Geräten Inc., ist ein Anhörungstechnologieunternehmen
widmete, eine Familie von Produkten zu liefern, um Kommunikationsfähigkeit zu verbessern, und
Qualität des Lebens für die Millionen von von Strom eingegrenzten anhörungsbeeinträchtigten Leuten
Anhörungslösungen.
Symphonix ` vibrierendes Soundbridge ist ein gestaltetes chirurgisches Implantat
zu arbeiten mit den natürlichen Strukturen des mittleren Ohrs, um zu hören zu verbessern, und
Kommunikationsfähigkeit für die Leute mit Anhörungsbeeinträchtigung.
Das Gerät kann sein
implantierte während eines Kurzschlusses, ambulanten Patienten medizinisches Verfahren.
Weitere Informationen über
Symphonix Geräte, Inc. kann bei oder durch Rufen gefunden werden
800-833-7733.

Auszüge machten in der Pressemitteilung bezüglich der Zukunft Leistung unser
Geschäft, unsere Marketinginitiativen einschließend, sind "vorausblickende Auszüge"
und sind zu einer Anzahl von Ungewißheiten, die tatsächliche Ergebnisse verursachen konnten, unterworfen
unterscheiden Sie sich materiell von den gemachten Auszügen.
Solche Risiken und Ungewißheiten
schließt ein, aber wird nicht zu eingegrenzt die Produkte des Unternehmens, die zu erreichen versäumen
verbreitete Marktannahme von otologists, audiologists und der Anhörung
beeinträchtigte, jene in das Militär und die Veteranen einbeziehen Verwaltung, und d
die Produkte des Unternehmens, die versäumen, Versicherungserstattung zu erhalten.
Weiter
Benachrichtigung auf potentiellen Faktoren, die das Unternehmen beeinflussen konnten, sind finanziell
resultiert sind in die Form des Unternehmens 10-Q für den Viertelausgang am 30. Juni einbezogen
2002, und zu formen 10 K für das 2001 mit den Wertpapieren gefeilte Geschäftsjahr und
Tauschprovision.

Notiz: Symphonix, vibrierend, und Soundbridge sind eingetragene Warenzeichen von Symphonix
Geräte, Inc.

[Viva-los-Tioz]

Hallo Symphoniker,

heute zwar keine News aber dafür große Umsätze in den USA (schon über 300k gehandelte Shares). Ich hoffe Smpx wartet noch ein wenig bis ich Anfang Dezember nachkaufen kann .

Gruß
Viva

[alanthegreenhorn]

Symphonix Announces Dissolution of Its Business

SAN JOSE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Symphonix Devices, Inc. (Nasdaq: SMPX) announced today that its Board of Directors has unanimously deemed advisable the dissolution of the company and approved a plan of complete liquidation and dissolution of its business. The Board of Directors made this decision after an unsuccessful process of pursuing various strategic alternatives, including potential partner arrangements and a sale of the company outright.

Kirk Davis, CEO and a Director of the company stated, "The slow market adoption of the Vibrant Soundbridge combined with the difficult current financing environment has led us to make this very difficult decision. However, upon careful consideration from our Directors, Officers and advisors, we believe that this action is in the best interests of our stockholders."

Symphonix expects to submit the plan of complete liquidation and dissolution of its business to stockholders for approval at a special meeting of the stockholders to be held on a future date to be set by the Board of Directors.

Statements made in the press release regarding the dissolution of the Company are "forward-looking statements" and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made. Such risks and uncertainties include but are not limited to a decision by the Company`s Board of Directors to pursue other alternatives, such as bankruptcy. Further information on potential factors that could affect the Company`s dissolution is included in the Company`s Form 10-Q for the quarter ended September 30, 2002 filed with the Securities and Exchange Commission.

CONTACT: media, Eric Gertsman of Neale-May & Partners, [phone], ext. 502, or [e-mail]; or Investors, [phone], or Customer Service, [phone], for Symphonix Devices, Inc.

[hoover]

na, da haben wir doch die günstigen nachkaufkurse!!!

muss ich wohl unter der rubrik "lehrgeld" abbuchen.

[Viva-los-Tioz]

Hallo Leute,

ich weiß nicht was ich dazu sagen soll aber ich bin total geschockt.Bin gerade nach Hause gekommen und kann es noch garnicht glauben.

Symphonix kündigt Auflösung von seinem Geschäft an

San JOSE, Calif, 14. Nov /PRNewswire-FirstCall/-symphonix Geräte, Inc. (Nasdaq: SMPX) kündigte heute an, daß sein Aufsichtsrat einstimmig die Auflösung vom Unternehmen als ratsam erachtet hat, und genehmigte einen Plan von vollständiger Liquidierung und Auflösung von ihrem Geschäft. Der Aufsichtsrat traf diese Entscheidung, nach einem erfolglosen Prozeß, verschiedenen strategischen Alternativen nachzugehen, als er potentielle Partneranordnungen und einen Verkauf des Unternehmens ganz einschloß.

Kirche Davis, Vorstandsvorsitzender und ein Direktor des Unternehmens, die angegeben sind, "die langsame Marktannahme des mit der schwierigen gegenwärtigen Finanzierungsumgebung verbundenen vibrierenden Soundbridges hat uns dazu geführt, diese sehr schwierige Entscheidung zu treffen. Jedoch glauben wir auf sorgfältiger Gegenleistung von unseren Direktoren, Leitern und Beratern, daß diese Aktion in den besten Zinsen unserer Aktionäre ist, ".

Es erwartet, daß Symphonix den Plan von vollständiger Liquidierung und die Auflösung von seinem Geschäft an Aktionäre abschickt, damit Einverständnis an einem speziellen Treffen von den Aktionären, an einem zukünftigen Datum gehalten zu werden, vom Aufsichtsrat gesetzt wird.

In der Pressemitteilung bezüglich der Auflösung des Unternehmens gemachte Auszüge sind "vorausblickende Auszüge" und sind abhängig von einer Anzahl von Ungewißheiten, die bewirken konnten, daß sich tatsächliche Ergebnisse materiell von den gemachten Auszügen unterscheiden. Solche Risiken und Ungewißheiten beinhalten, aber werden nicht auf eine Entscheidung vom Aufsichtsrat des Unternehmens beschränkt, um anderen Alternativen wie Konkurs nachzugehen. Weitere Benachrichtigung auf potentiellen Faktoren, die die Auflösung des Unternehmens beeinflussen konnten, ist in die Form des Unternehmens mit der Wertpapier- und Tauschprovision einbezogen, die 10-Q für das Viertel September als 30, gefeilte 2002 beendete.

[Flickus]

@Viva-los-Tioz:
Hi Alter, wars das oder fällt denen noch was ein?
Gut daß das bei aller Traurigkeit vor dem Weihnachtsgeld kam, also müssen wir noch das posive darin sehen.
Bis dann

[Viva-los-Tioz]

Hallo Flickus,

ich bin total geschockt(war wohl zu sehr überzeugt von Smpx),ich habe gerade mal ein paar Mails nach Siemens geschickt(vielleicht wissen die mehr).

Ich kann im Moment nicht sagen was jetzt noch kommen wird.


Gruß
Viva

[alanthegreenhorn]

Frage mich nur warum bei der letzten Veröffentlichung ein Ausblick auf 2003 gegeben wurde und nun die Liquidation so mir nichts dir nichts beschlossen werden soll??????????????????????????????

[Viva-los-Tioz]

@alanthegreenhorn

Das verstehe ich auch nicht,so wie sie es immer dargestellt haben lief doch angeblich alles nach Plan.

Was meinst Du was jetzt noch passieren könnte?


Gruß
Viva

[Viva-los-Tioz]

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 14, 2002

SYMPHONIX DEVICES, INC.

--------------------------------------------------------------------------------

(Exact name of registrant as specified in its charter)

Delaware
--------------------------------------------------------------------------------
000-23767
--------------------------------------------------------------------------------
77-0376250
--------------------------------------------------------------------------------

(State or other jurisdiction
of incorporation) (Commission
File Number) (I.R.S. Employer
Identification No.)



2331 Zanker Road, San Jose, California
--------------------------------------------------------------------------------
95131-1109
--------------------------------------------------------------------------------


(Address of principal executive offices) (Zip Code)



Registrant’s telephone number, including area code [phone]
--------------------------------------------------------------------------------





--------------------------------------------------------------------------------

(Former name or former address, if changed since last report)




--------------------------------------------------------------------------------


Item 5. Other Events

On November 13, 2002, the Board of Directors of Symphonix Devices, Inc. deemed advisable the dissolution of the company and approved a plan of complete liquidation and dissolution for which Symphonix will seek stockholder approval. Symphonix expects to liquidate all assets, including its intellectual property.


Attached and incorporated herein are a form of plan of complete liquidation and dissolution and a press release disseminated by Symphonix on November 14, 2002 in connection with the proposed dissolution.

Item 7. Financial Statements and Exhibits

(c) Exhibits

2.1 Form of Plan of Complete Liquidation and Dissolution.

99.1 Press release dated November 14, 2002.


2


--------------------------------------------------------------------------------


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SYMPHONIX DEVICES, INC.

/s/ K IRK B. D AVIS
--------------------------------------------------------------------------------

Kirk B. Davis
President and Chief Executive Officer
Date: November 14, 2002


3




--------------------------------------------------------------------------------


Exhibit Index

Exhibit No.
--------------------------------------------------------------------------------

2.1 Form of Plan of Complete Liquidation and Dissolution.

99.1 Press release dated November 14, 2002.


4

--------------------------------------------------------------------------------




Exhibit 2.1


PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION OF

SYMPHONIX DEVICES, INC.

This Plan of Complete Liquidation and Dissolution (the “Plan”) is intended to accomplish the complete liquidation and dissolution of Symphonix Devices, Inc., Inc., a Delaware corporation (the “Company”), in accordance with the Delaware General Corporation Law (the “DGCL”) and Sections 331 and 336 of the Internal Revenue Code of 1986, as amended (the “Code”), as follows:

1. The Board of Directors of the Company (the “Board of Directors”) has adopted this Plan and called a meeting (the “Meeting”) of the holders of the Company’s Common Stock to take action on the Plan and ratify the Company’s actions taken to date on the Plan. If stockholders holding a majority of the Company’s outstanding common stock, par value $0.001 per share (the “Common Stock”), vote for the adoption of this Plan at the Meeting, the Plan shall constitute the adopted Plan of the Company as of the date of the Meeting, or such later date on which the stockholders may approve the Plan if the Meeting is adjourned to a later date (the “Adoption Date”).

2. After the Adoption Date, the Company shall not engage in any business activities except to the extent necessary to preserve the value of its assets, wind up its business affairs, and distribute its assets in accordance with this Plan. No later than thirty (30) days following the Adoption Date, the Company shall file Form 966 with the Internal Revenue Service.

3. From and after the Adoption Date, the Company shall complete the following corporate actions: The Board of Directors will liquidate the Company’s assets in accordance with any applicable provision of the DGCL, including Sections 280 and 281. Without limiting the flexibility of the Board of Directors, the Board of Directors may, at it option, instruct the officers of the Company to follow the procedures set forth in Sections 280 and 281 of the DGCL which instruct such officers to: (i) give notice of the dissolution to all persons having a claim against the Company and provide for the rejection of any such claims in accordance with Section 280 of the DGCL; (ii) offer to any claimant on a contract whose claim is contingent, conditional or unmatured, security in an amount sufficient to provide compensation to the claimant if the claim matures, and petition the Delaware Court of Chancery to determine the amount and form of security sufficient to provide compensation to any such claimant who rejects such offer in accordance with Section 280 of the DGCL; (iii) petition the Delaware Court of Chancery to determine the amount and form of security which would be reasonably likely to be sufficient to provide compensation for (A) claims that are the subject of pending litigation against the Company, and (B) claims that have not been made known to the Company at the time of dissolution, but are likely to arise or become known within five (5) years (or longer in the discretion of the Delaware Court of Chancery), each in accordance with Section 280 of the DGCL; (iv) pay, or make adequate provision for payment, of all claims made against the Company and not rejected, including all expenses of the sale of assets and of the liquidation and dissolution provided for by the Plan in accordance with Section 280 of the DGCL; and (v) post all

1


--------------------------------------------------------------------------------

security offered and not rejected and all security ordered by the Delaware Court of Chancery in accordance with Section 280 of the DGCL.

4. The distributions to the stockholders pursuant to Section 3, 6 and 7 hereof shall be in complete redemption and cancellation of all of the outstanding Common Stock of the Company. As a condition to receipt of any distribution to the Company’s stockholders, the Board of Directors or the Trustees (as defined below), in their absolute discretion, may require the stockholders to (i) surrender their certificates evidencing the Common Stock to the Company or its agents for recording of such distributions thereon or (ii) furnish the Company with evidence satisfactory to the Board of Directors or the Trustees of the loss, theft or destruction of their certificates evidencing the Common Stock, together with such surety bond or other security or indemnity as may be required by and satisfactory to the Board of Directors or the Trustees (“Satisfactory Evidence and Indemnity”). The Company will finally close its stock transfer books and discontinue recording transfers of Common Stock on the earliest to occur of (i) the close of business on the record date fixed by the Board of Directors for the final liquidating distribution, (ii) the close of business on the date on which the remaining assets of the Company are transferred to the Trust or (iii) the date on which the Company files its Certificate of Dissolution under the DGCL (following any post-dissolution continuation period thereunder), and thereafter certificates representing Common Stock will not be assignable or transferable on the books of the Company except by will, intestate succession, or operation of law.

5. If any distribution to a stockholder cannot be made, whether because the stockholder cannot be located, has not surrendered its certificates evidencing the Common Stock as required hereunder or for any other reason, the distribution to which such stockholder is entitled (unless transferred to the Trust established pursuant to Section 6 hereof) shall be transferred, at such time as the final liquidating distribution is made by the Company, to the official of such state or other jurisdiction authorized by applicable law to receive the proceeds of such distribution. The proceeds of such distribution shall thereafter be held solely for the benefit of and for ultimate distribution to such stockholder as the sole equitable owner thereof and shall be treated as abandoned property and escheat to the applicable state or other jurisdiction in accordance with applicable law. In no event shall the proceeds of any such distribution revert to or become the property of the Company.

6. If deemed necessary, appropriate or desirable by the Board of Directors, in its absolute discretion, in furtherance of the liquidation and distribution of the Company’s assets to the stockholders, as a final liquidating distribution or from time to time, the Company shall transfer to one or more liquidating trustees, for the benefit of its stockholders (the “Trustees”), under a liquidating trust (the “Trust”), any assets of the Company which are (i) not reasonably susceptible to distribution to the stockholders, including without limitation non-cash assets and assets held on behalf of the stockholders (a) who cannot be located or who do not tender their certificates evidencing the Common Stock to the Company or its agent as herein above required or (b) to whom distributions may not be made based upon restrictions under contract or law, including, without limitation, restrictions of the Federal securities laws and regulations promulgated thereunder, or (ii) held as the Contingency Reserve. The Board of Directors is hereby authorized to appoint one or more individuals, corporations, partnerships or other persons, or any combination thereof, including, without limitation, any one or more officers, directors, employees, agents or representatives of the Company, to act as the initial Trustee or Trustees for the benefit of the stockholders and to receive any assets of the Company. Any Trustees appointed as provided in the preceding sentence shall

2


--------------------------------------------------------------------------------

succeed to all right, title and interest of the Company of any kind and character with respect to such transferred assets and, to the extent of the assets so transferred and solely in their capacity as Trustees, shall assume all of the liabilities and obligations of the Company, including, without limitation, any unsatisfied claims and unascertained or contingent liabilities. Further, any conveyance of assets to the Trustees shall be deemed to be a distribution of property and assets by the Company to the stockholders for the purposes of Section 3 of this Plan. Any such conveyance to the Trustees shall be in trust for the stockholders of the Company. The Company, subject to this Section and as authorized by the Board of Directors, in its absolute discretion, may enter into a liquidating trust agreement with the Trustees, on such terms and conditions as the Board of Directors, in its absolute discretion, may deem necessary, appropriate or desirable. Adoption of this Plan by a majority of the outstanding Common Stock shall constitute the approval of the stockholders of any such appointment, any such liquidating trust agreement and any transfer of assets by the Company to the Trust as their act and as a part hereof as if herein written.

7. Whether or not a Trust shall have been previously established pursuant to Section 6, in the event it should not be feasible for the Company to make the final distribution to its stockholders of all assets and properties of the Company prior to [____________], 2005 then, on or before such date, the Company shall be required to establish a Trust and transfer any remaining assets and properties (including, without limitation, any uncollected claims, contingent assets and the Contingency Reserve) to the Trustees as set forth in Section 6.

8. After the Adoption Date, the officers of the Company shall, at such time as the Board of Directors, in its absolute discretion, deems necessary, appropriate or desirable, obtain any certificates required from the Delaware tax authorities and, upon obtaining such certificates, the Company shall file with the Secretary of State of the State of Delaware a certificate of dissolution (the “Certificate of Dissolution”) in accordance with the DGCL.

9. Adoption of this Plan by holders of a majority of the outstanding Common Stock shall constitute the approval of the stockholders of the sale, exchange or other disposition in liquidation of all of the property and assets of the Company, including any sale, exchange or other disposition in liquidation of less than a majority of the property and assets of the Company to affiliates of the Company, whether such sale, exchange or other disposition occurs in one transaction or a series of transactions, and shall constitute ratification of all contracts for sale, exchange or other disposition which are conditioned on adoption of this Plan.

10. In connection with and for the purposes of implementing and assuring completion of this Plan, the Company may, in the absolute discretion of the Board of Directors, pay any brokerage, agency, professional, legal and other fees and expenses of persons rendering services to the Company in connection with the collection, sale, exchange or other disposition of the Company’s property and assets and the implementation of this Plan. Adoption of the Plan shall constitute approval of such payments by the stockholders of the Company.

11. In connection with and for the purpose of implementing and assuring completion of this Plan, the Company may, in the absolute discretion of the Board of Directors, pay the Company’s officers, directors, employees, agents and representatives, or any of them, compensation or additional compensation above their regular compensation, in money or other property, as severance,

3


--------------------------------------------------------------------------------

bonus, acceleration of vesting of stock or stock options, or in any other form, in recognition of the extraordinary efforts they, or any of them, will be required to undertake, or actually undertake, in connection with the implementation of this Plan. Adoption of this Plan by a majority of the outstanding Common Stock shall constitute the approval of the Company’s stockholders of the payment of any such compensation.

12. The Company shall continue to indemnify its officers, directors, employees, agents and representatives in accordance with its certificate of incorporation, as amended, and Bylaws and any contractual arrangements, for the actions taken in connection with this Plan and the winding up of the affairs of the Company. The Company’s obligation to indemnify such persons may also be satisfied out of the assets of the Trust. The Board of Directors and the Trustees, in their absolute discretion, are authorized to obtain and maintain insurance as may be necessary or appropriate to cover the Company’s obligation hereunder, including seeking an extension in time and coverage of the Company’s insurance policies currently in effect.

13. Notwithstanding authorization or consent to this Plan and the transactions contemplated hereby by the Company’s stockholders, the Board of Directors may modify, amend or abandon this Plan and the transactions contemplated hereby without further action by the stockholders to the extent permitted by the DGCL.

14. The Board of Directors of the Company is hereby authorized, without further action by the Company’s stockholders, to do and perform or cause the officers of the Company, subject to approval of the Board of Directors, to do and perform, any and all acts, and to make, execute, deliver or adopt any and all agreements, resolutions, conveyances, certificates and other documents of every kind which are deemed necessary, appropriate or desirable, in the absolute discretion of the Board of Directors, to implement this Plan and the transaction contemplated hereby, including, without limiting the foregoing, all filings or acts required by any state or federal law or regulation to wind up its affairs.

4




Exhibit 99.1


SYMPHONIX ANNOUNCES DISSOLUTION

OF ITS BUSINESS

SAN JOSE, Calif. — November 14, 2002 — Symphonix Devices, Inc. (NASDAQ: SMPX) announced today that its Board of Directors has unanimously deemed advisable the dissolution of the company and approved a plan of complete liquidation and dissolution of its business. The Board of Directors made this decision after an unsuccessful process of pursuing various strategic alternatives, including potential partner arrangements and a sale of the company outright.

Kirk Davis, CEO and a Director of the company stated, “The slow market adoption of the Vibrant Soundbridge combined with the difficult current financing environment has led us to make this very difficult decision. However, upon careful consideration from our Directors, Officers and advisors, we believe that this action is in the best interests of our stockholders.”

Symphonix expects to submit the plan of complete liquidation and dissolution of its business to stockholders for approval at a special meeting of the stockholders to be held on a future date to be set by the Board of Directors.

# # #

Statements made in the press release regarding the dissolution of the Company are “forward looking statements” and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made. Such risks and uncertainties include but are not limited to a decision by the Company’s Board of Directors to pursue other alternatives, such as bankruptcy. Further information on potential factors that could affect the Company’s dissolution is included in the Company’s Form 10-Q for the quarter ended September 30, 2002 filed with the Securities and Exchange Commission.

For more information, please contact:

Investor Contact:
Investor Relations:
[phone]

Customer Contact:
Customer Service:
[phone]

Media Contact:
Eric Gertsman
Neale-May & Partners
[phone] x502
[e-mail]

1


powered by EDGAR Online

[Viva-los-Tioz]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2002.


OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO .


COMMISSION FILE NO. 000-23767

SYMPHONIX DEVICES, INC.
(Exact name of registrant as specified in its charter)

DELAWARE 77-0376250
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)


2331 Zanker Road
SAN JOSE, CALIFORNIA 95131-1107
(Address of principal executive offices, including zip code)

[phone]
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes X No


--------------------------------------------------------------------------------


As of September 30, 2002; 35,832,000 shares of the Registrant’s Common Stock were outstanding.


--------------------------------------------------------------------------------



--------------------------------------------------------------------------------

Table of Contents
SYMPHONIX DEVICES, INC.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

Condensed Consolidated Balance Sheets as of September 30, 2002 and December 31, 2001 1

Condensed Consolidated Statements of Operations for the three months and nine months ended September 30, 2002 and 2001 2

Condensed Consolidated Statements of Comprehensive Loss for the three months and nine months ended September 30, 2002 and 2001 3

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2002 and 2001 4

Notes to Condensed Consolidated Financial Statements 5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 7

Item 3. Quantitative and Qualitative Disclosures About Market Risk 18

Item 4. Disclosure Controls and Procedures 18

PART II. OTHER INFORMATION

Item 1. Legal Proceedings 19

Item 2. Changes in Securities and Use of Proceeds 19

Item 3. Defaults Upon Senior Securities 19

Item 4. Submission of Matters to a Vote of Security Holders 19

Item 5. Other Information 19

Item 6. Exhibits and Reports on Form 8-K 19



i


--------------------------------------------------------------------------------

Table of Contents

PART I. FINANCIAL INFORMATION



Item 1. Financial Statements

SYMPHONIX DEVICES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)


September 30,
2002
--------------------------------------------------------------------------------
December 31,
2001
--------------------------------------------------------------------------------

(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 3,897 $ 1,343
Short-term investments — 10,774
Restricted cash 549 —
Accounts receivable, net 245 329
Inventories 747 656
Prepaid expenses and other current assets 434 566

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Total current assets 5,872 13,668
Property and equipment, net 836 1,313
Restricted cash 135 174

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Total assets $ 6,843 $ 15,155

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 291 $ 451
Accrued compensation 730 976
Other accrued liabilities 1,396 2,708
Current portion of bank borrowings 500 500

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Total current liabilities 2,917 4,635
Deferred revenue 453 732
Bank borrowings, less current portion 125 500

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Total liabilities 3,495 5,867

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Stockholders’ equity:
Common stock 36 36
Notes receivable from stockholders (400 ) (400 )
Additional paid-in capital 92,110 92,107
Accumulated other comprehensive income 66 260
Accumulated deficit (88,464 ) (82,715 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Total stockholders’ equity 3,348 9,288

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Total liabilities and stockholders’ equity $ 6,843 $ 15,155

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------



The accompanying notes are an integral part of these condensed consolidated financial statements.

1


--------------------------------------------------------------------------------

Table of Contents
SYMPHONIX DEVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)


Three months ended September 30,
--------------------------------------------------------------------------------
Nine months ended September 30,
--------------------------------------------------------------------------------

2002
--------------------------------------------------------------------------------
2001
--------------------------------------------------------------------------------
2002
--------------------------------------------------------------------------------
2001
--------------------------------------------------------------------------------

Revenue $ 404 $ 535 $ 1,397 $ 1,546

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Costs and expenses:
Cost of goods sold 420 1,342 1,289 3,665
Research and development 526 1,406 1,904 4,927
Selling, general and administrative 1,365 1,817 4,337 7,318

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Total costs and expenses 2,311 4,565 7,530 15,910

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Operating loss (1,907 ) (4,030 ) (6,133 ) (14,364 )
Interest income 42 271 429 747
Interest expense (11 ) (29 ) (45 ) (91 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Net loss $ (1,876 ) $ (3,788 ) $ (5,749 ) $ (13,708 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Basic and diluted net loss per common share $ (0.05 ) $ (0.11 ) $ (0.16 ) $ (0.54 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Shares used in computing basic and diluted
net loss per common share 35,803 33,399 35,710 25,190

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------



The accompanying notes are an integral part of these condensed consolidated financial statements.

2


--------------------------------------------------------------------------------

Table of Contents
SYMPHONIX DEVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands)
(unaudited)

Three months ended
September 30,
--------------------------------------------------------------------------------
Nine months ended September 30,
--------------------------------------------------------------------------------

2002
--------------------------------------------------------------------------------
2001
--------------------------------------------------------------------------------
2002
--------------------------------------------------------------------------------
2001
--------------------------------------------------------------------------------

Net loss $ (1,876 ) $ (3,788 ) $ (5,749 ) $ (13,708 )
Change in unrealized gain on short-term investments (6 ) 99 (180 ) 204
Translation adjustments 4 (1 ) (14 ) 7

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Comprehensive loss $ (1,878 ) $ (3,690 ) $ (5,943 ) $ (13,497 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------



The accompanying notes are an integral part of these condensed consolidated financial statements.

3


--------------------------------------------------------------------------------

Table of Contents
SYMPHONIX DEVICES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)


Nine months ended September 30,
--------------------------------------------------------------------------------

2002
--------------------------------------------------------------------------------
2001
--------------------------------------------------------------------------------

Cash flows from operating activities:
Net loss $ (5,749 ) $ (13,708 )
Adjustments to reconcile net loss to cash used in operating activities:
Amortization of deferred compensation — 34
Depreciation and amortization 494 590
Amortization of premium on short-term investments 50 125
Gain on sale of short-term investments (48 ) (7 )
Changes in operating assets and liabilities:
Accounts receivable 84 (119 )
Inventories (91 ) 1,101
Prepaid expenses and other current assets 132 93
Accounts payable (160 ) (569 )
Accrued compensation (246 ) (131 )
Deferred revenue (279 ) (281 )
Other accrued liabilities (1,312 ) (1,075 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Net cash used in operating activities (7,125 ) (13,947 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Cash flows from investing activities
Purchases of short-term investments — (27,380 )
Sales and maturities of short-term and long-term investments 10,592 13,326
Purchases of property and equipment (17 ) (708 )
Increase in restricted cash (510 ) (222 )
Change in other assets — 19

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Net cash provided by (used in) investing activities 10,065 (14,965 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Cash flows from financing activities
Payments on bank borrowings (375 ) (375 )
Proceeds from issuance of common stock 3 238
Payments on stockholders notes receivable — 21

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Net cash used in financing activities (372 ) (116 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Net increase (decrease) in cash and cash equivalents 2,568 (29,028 )
Effect of exchange rates on cash and cash equivalents (14 ) 7
Cash and cash equivalents, beginning of period 1,343 29,535

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Cash and cash equivalents, end of period $ 3,897 $ 514

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------



The accompanying notes are an integral part of these condensed consolidated financial statements.

4


--------------------------------------------------------------------------------

Table of Contents
SYMPHONIX DEVICES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation:

The accompanying unaudited condensed consolidated financial statements as of September 30, 2002 of Symphonix Devices, Inc. (the “Company” or “Symphonix”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation. Operating results for the three and nine months ended September 30, 2002 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2002, or any future interim period.

These financial statements and notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2001 and footnotes thereto, included in the Company’s Annual Report on Form 10-K.

These financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has sustained significant losses for the last several years. As discussed in Note 6, the Company’s Board of Directors have approved a plan of complete dissolution and liquidation. The current value of the assets may not be realized upon dissolution and liquidation.

2. Computation of Basic and Diluted Net Loss per Common Share:

Basic earnings per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities, if dilutive. The following table is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted EPS calculations and sets forth potential shares of common stock that are not included in the diluted net loss per share calculation as their effect is antidilutive (in thousands, except per share data):

5


--------------------------------------------------------------------------------

Table of Contents

SYMPHONIX DEVICES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)


Three months ended September 30,
--------------------------------------------------------------------------------
Nine months ended September 30,
--------------------------------------------------------------------------------

2002
--------------------------------------------------------------------------------
2001
--------------------------------------------------------------------------------
2002
--------------------------------------------------------------------------------
2001
--------------------------------------------------------------------------------

Numerator—Basic and Diluted
Net loss $ (1,876 ) $ (3,788 ) $ (5,749 ) $ (13,708 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Denominator—Basic and Diluted
Weighted average common shares outstanding 35,830 33,451 35,743 25,248
Weighted average unvested common shares subject to repurchase (27 ) (52 ) (33 ) (58 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Total 35,803 33,399 35,710 25,190

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Basic and diluted net loss per common share $ (0.05 ) $ (0.11 ) $ (0.16 ) $ (0.54 )

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Antidilutive Securities:
Options to purchase common stock 5,084 3,650 5,084 3,650
Common stock subject to repurchase 23 48 23 48
Warrants 7 7 7 7

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

5,114 3,705 5,114 3,705

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------



3. Inventories:

Inventories comprise (in thousands):

September 30, 2002
--------------------------------------------------------------------------------
December 31, 2001
--------------------------------------------------------------------------------

Raw materials $ 390 $ 227
Work in progress 282 340
Finished goods 75 89

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

$ 747 $ 656

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------



4. Restricted Cash:

As of September 30, 2002, the Company held $625,000 in a certificate of deposit with a financial institution to comply with existing loan covenants as outlined in an amended loan agreement. The amount required to be held in a certificate of deposit will be reduced as the Company makes payments on the outstanding loan balance. In addition, the Company has outstanding letters of credit in the amount of $59,000 which are collateralized by certificates of deposit of this amount.

5. Recent Accounting Pronouncements

In August 2001, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards No. 143, (“SFAS 143”), “ Accounting for Asset Retirement Obligations,” which is effective for fiscal years beginning after June 15, 2002. SFAS 143

6


--------------------------------------------------------------------------------

Table of Contents

SYMPHONIX DEVICES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. The Company believes that the adoption of SFAS 143 will not have a material impact on the consolidated financial position or results of operations of the Company.

In April of 2002, the FASB issued Statement of Financial Accounting Standards No. 145 (“SFAS 145”), “ Rescission of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical Corrections,” which is effective for fiscal years beginning after May 15, 2002. Under SFAS 145, gains and losses from the extinguishment of debt should be classified as extraordinary items only if they meet the criteria of Accounting Principles Board Opinion No. 30. SFAS also addresses financial accounting and reporting for capital leases that are modified in such a way as to give rise to a new agreement classified as an operating lease. The Company believes that the adoption of SFAS 145 will not have a material impact on the consolidated financial position or results of the operations of the Company.

In June of 2002, the FASB issued Statement of Financial Accounting Standards No. 146 (“SFAS 146”), “ Accounting for Costs Associated with Exit or Disposal Activities,” which is effective for exit or disposal activities initiated after December 31, 2002. SFAS 146 nullifies Emerging Issues Task Force Issue No. 94-3 , “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring) .” Under SFAS 146, a liability is required to be recognized for a cost associated with an exit or disposal activity when the liability is incurred. SFAS 146 applies to costs associated with an exit activity that does not involve an entity newly acquired in a business combination or with a retirement or disposal activity covered by FASB Statements No. 143 and 144. The Company believes that the adoption of SFAS 146 will not have a material impact on the consolidated financial position or results of the operations of the Company.

6. Subsequent Event

On November 13, 2002, the Company’s Board of Directors approved a plan of complete dissolution and liquidation, subject to approval by the Company’s stockholders at a special meeting to be held at a future date set by the Company’s Board of Directors. In connection with the proposed liquidation, the Company expects to terminate the majority of its employees and retain only a limited number of personnel necessary to facilitate the liquidation process. Additionally, the Company intends to liquidate all the property, equipment, intellectual property and other assets and may consider various legal alternatives to liquidating the Company including bankruptcy. The current value of the assets may not be realized upon dissolution and liquidation.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operations which express that the company “believes”, “anticipates” or “plans to” as well as other statements which are not historical fact, are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially as a result of the risks and uncertainties described herein and elsewhere including, in particular, those factors described under “Factors That May Affect Future Results.”

Overview

Symphonix has developed a family of proprietary implantable Soundbridges for the management of mild to severe hearing impairment. Our family of Vibrant Soundbridges is based on our patented core Floating Mass Transducer, or FMT, technology. Late in 2000, we received

7


--------------------------------------------------------------------------------

Table of Contents
approval from the Food and Drug Administration, or FDA, to commercially market our products in the United States. Subsequent to FDA approval, our products were launched to the otology community and audiology community.

Symphonix’s Board of Directors approved a plan of complete dissolution and liquidation on November 13, 2002, subject to approval by our stockholders at a special meeting to be held at a future date set by our Board of Directors. In connection with the proposed liquidation, we expect to terminate the majority of our employees. We expect to retain only a limited number of personnel necessary to facilitate the liquidation process. In connection with the liquidation, we intend to liquidate our property, equipment, intellectual property and other assets. In addition, we may consider various legal alternatives to liquidating the Company, including bankruptcy.

Results of Operations

Revenue. Revenue was $0.4 million in the three months ended September 30, 2002 compared to $0.5 million in the three months ended September 30, 2001. Revenue was $1.4 million in the nine months ended September 30, 2002 compared to $1.5 million in the nine months ended September 30, 2001. Revenue in all periods was the result of selling activities to our distributor in Europe and direct sales in the United States. Revenue in the nine months ended September 30, 2002 and 2001 included $290,000 and $285,000, respectively, representing the amortization of the difference between the purchase price and fair value of the Company’s common stock purchased by

8


--------------------------------------------------------------------------------

Table of Contents
Siemens in connection with a Marketing and Distribution Agreement. The remaining deferred income will be amortized over the life of the agreement.

Cost of Goods Sold. Cost of goods sold decreased to $0.4 million for the three months ended September 30, 2002 from $1.3 million for the three months ended September 30, 2001 and decreased to $1.3 million for the nine months ended September 30, 2002 from $3.7 million for the nine months ended September 30, 2001. Cost of goods sold represents the direct cost of the products sold as well as manufacturing variances and accrued warranty. The decreases in cost of goods sold for both the three months and nine months ended September 30, 2002 are the result of reductions in warranty costs, lower manufacturing overhead and reduced direct labor costs. Warranty costs have decreased significantly due to the fact that we have cycled through most of the installed base of our older version audio processor and have replaced it with our newer audio processor that is substantially more reliable. Due to continued implementation of serviceability and reliability improvements we expect that our warranty costs will continue to decline in the future.

Research and Development Expenses. Research and development expenses decreased to $0.5 million in the three months ended September 30, 2002 compared to $1.4 million in the three months ended September 30, 2001. Research and development expenses decreased to $1.9 million for the nine months ended September 30, 2002 compared to $4.9 million for the nine months ended September 30, 2001. Decreases in research and development spending are due to the completion of a number of key research and development milestones during 2001 and 2002 and reflects the reduced level of investment in the totally-implantable Vibrant Soundbridge. These factors resulted in lower headcount, consulting and project costs during the three months and nine months ended September 30, 2002 compared to the same periods in 2001. Research and development expenses consist primarily of personnel costs, professional services, materials, supplies and equipment in support of product development, clinical trials, regulatory submissions, and the preparation and filing of patent applications.

Selling, General and Administrative Expenses. Selling, general and administrative expenses were $1.4 million in the three months ended September 30, 2002 compared to $1.8 million in the three months ended September 30, 2001 and were $4.3 million for the nine months ended September 30, 2002 compared to $7.3 million for the nine months ended September 30, 2001. Decreases in selling, general and administrative spending are primarily due to certain marketing activities in support of the Company’s product introduction post FDA approval that occurred in 2001 and not in 2002. This reduction is also due to expense reductions implemented by Symphonix in late 2001 and continued in 2002. Selling, general and administrative expenses consist primarily of personnel costs, promotional costs, legal and consulting costs.

Interest Income (Expense). Interest income, net of expense, decreased to $31,000 in the three months ended September 30, 2002 from $0.2 million in the three months ended September 30, 2001 and decreased to $0.4 million for the nine months ended September 30, 2002 from $0.7 million for the nine months ended September 30, 2001. The decrease in net interest income for the three and nine months ended September 30, 2002 compared to the same periods ended September 30, 2001 was due to the decrease in the Company’s cash and short-term investment balances as well as a decrease in interest rates. Interest earned in the future will depend on prevailing interest rates.

9


--------------------------------------------------------------------------------

Table of Contents
Income Taxes. To date, the Company has not incurred any U.S. income tax obligations. At December 31, 2001, the Company had net operating loss carryforwards of approximately $74.9 million for federal and $39.0 million for state income tax purposes, which will expire at various dates through 2021 and 2011, respectively, if not utilized. The principal differences between losses for financial and tax reporting purposes are the result of the capitalization of research and development and start-up expenses for tax purposes. Federal and state tax laws contain provisions that may limit the net operating loss carryforwards that can be used in any given year, should certain changes in the beneficial ownership of the Company’s outstanding common stock occur. Such events could limit the future of the Company’s net operating loss carryforwards.

Liquidity and Capital Resources

Since inception, the Company has primarily funded its operations and its capital investments from proceeds from its initial public offering completed in February 1998 totaling $28.4 million, from the private sale of equity securities totaling approximately $62.5 million, from an equipment lease financing totaling $1.3 million and from bank borrowings totaling $2.0 million. At September 30, 2002, the Company had $3.0 million in working capital, and its primary source of liquidity was $3.9 million in cash and cash equivalents. Additionally, the Company had $0.7 million of short-term and long-term restricted cash held in certificates of deposit as collateral for a bank loan and letters of credit.

Symphonix used $7.1 million in cash for operations in the nine months ended September 30, 2002 compared to $13.9 million in the nine months ended September 30, 2001 primarily in funding its operating losses. This reduction is due to expense reductions implemented by Symphonix in late 2001 and continued in 2002.

Capital expenditures, primarily related to the Company’s research and development and manufacturing activities, were $17,000 and $708,000 in the nine months ended September 30, 2002 and 2001, respectively. The reduction in capital expenditures is due to the completion of key milestones in research and development during 2001 and 2002. At September 30, 2002, the Company did not have any material commitments for capital expenditures.

The Company has a loan agreement with a bank that provided for borrowings of up to $2.0 million and for the issuance of letters of credit up to $250,000. At September 30, 2002, the Company had borrowings outstanding of $625,000, outstanding letters of credit in the amount of $59,000 and no amounts available for future borrowings under the loan agreement. Borrowings under the loan agreement are repayable over four years commencing in January 2000.

In connection with the proposed liquidation, we expect to liquidate our remaining assets, including property, equipment and intellectual property. We also expect to incur and pay liquidation expenses, in addition to payments of ongoing operating expenses and settlement of existing and potential obligations. Liquidation expenses may include, among others, employee severance and related costs, customer warranty obligations and legal and accounting fees. While we cannot currently make a precise estimate of these expenses, we believe that most if not all of our current cash and cash equivalents, together with proceeds from future sales of the remaining assets may be required to pay for the above expenditures.

10


--------------------------------------------------------------------------------

Table of Contents

Recent Accounting Pronouncements

In August 2001, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards No. 143, (“SFAS 143”), “ Accounting for Asset Retirement Obligations,” which is effective for fiscal years beginning after June 15, 2002. SFAS 143 addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. The Company believes that the adoption of SFAS 143 will not have a material impact on the consolidated financial position or results of operations of the Company.

In April of 2002, the FASB issued Statement of Financial Accounting Standards No. 145 (“SFAS 145”), “ Rescission of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical Corrections,” which is effective for fiscal years beginning after May 15, 2002. Under SFAS 145, gains and losses from the extinguishment of debt should be classified as extraordinary items only if they meet the criteria of Accounting Principles Board Opinion No. 30. SFAS also addresses financial accounting and reporting for capital leases that are modified in such a way as to give rise to a new agreement classified as an operating lease. The Company believes that the adoption of SFAS 145 will not have a material impact on the consolidated financial position or results of the operations of the Company.

In June of 2002, the FASB issued Statement of Financial Accounting Standards No. 146 (“SFAS 146”), “ Accounting for Costs Associated with Exit or Disposal Activities,” which is effective for exit or disposal activities initiated after December 31, 2002. SFAS 146 nullifies Emerging Issues Task Force Issue No. 94-3 , “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring) .” Under SFAS 146, a liability is required to be recognized for a cost associated with an exit or disposal activity when the liability is incurred. SFAS 146 applies to costs associated with an exit activity that does not involve an entity newly acquired in a business combination or with a retirement or disposal activity covered by FASB Statements No. 143 and 144. The Company believes that the adoption of SFAS 146 will not have a material impact on the consolidated financial position or results of the operations of the Company.

Factors That May Affect Future Results

WE CANNOT ASSURE YOU OF THE AMOUNT, IF ANY, OF ANY DISTRIBUTION TO OUR STOCKHOLDERS UNDER THE PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION.

Liquidation and dissolution may not create value to our stockholders or result in any remaining capital for distribution to our stockholders. We cannot assure you of the precise nature and amount of any distribution to our stockholders pursuant to our Plan of Complete Liquidation and Dissolution. Uncertainties as to the precise net value of our non-cash assets and the ultimate amount of our liabilities make it impracticable to predict the aggregate net value, if any, ultimately distributable to our stockholders. The aggregate net value, if any, ultimately distributable to you under the Plan may be lower or higher than the amount you would receive if you sold your shares of our common stock prior to the time we file the Certificate of Dissolution with the Delaware Secretary of State. The actual nature and amount of all distributions will depend in part upon our ability to convert our remaining non-cash assets into cash. We may not be successful in selling our non-cash assets, in which case we may not generate meaningful cash, if any, to return to our stockholders.

11


--------------------------------------------------------------------------------

Table of Contents

THE PROCEEDS FROM ANY SALES OF OUR NON-CASH ASSETS MAY BE LESS THAN ANTICIPATED.

Sales of our non-cash assets will be made on terms approved by our Board of Directors and may be conducted by competitive bidding, public sales or privately negotiated sales. The prices at which we will be able to sell our various non-cash assets will depend largely on factors beyond our control, including, without limitation, the condition of financial markets, the availability of financing to prospective purchasers of the assets, regulatory approvals, public market perceptions, and limitations on transferability of certain non-cash assets. In addition, we may not obtain as high a price for a particular asset as we might secure if we were not in liquidation. Furthermore, many of our non-cash assets, particularly our intellectual property, will decline in value over time, and we may not be able to consummate the sale of these assets in time to generate meaningful value, which could be returned to our stockholders.

12


--------------------------------------------------------------------------------

Table of Contents

WE MAY NOT BE ABLE TO SETTLE ALL OF OUR OBLIGATIONS TO CREDITORS.

We have certain current and future obligations to creditors. These include, without limitation, a note payable to a bank, trade accounts payable, as well as warranty claims. As part of the wind down process, we will attempt to settle our obligations with our creditors and are currently exploring all our options in this regard. We may not, however, succeed in doing so. If we cannot reach an agreement with a creditor concerning an obligation, that creditor may choose to bring a lawsuit against us. Any litigation could delay or even prevent us from completing the Plan. Moreover, amounts required to settle our obligations will reduce or eliminate the amount of remaining capital available for distribution to stockholders.

13


--------------------------------------------------------------------------------

Table of Contents

WE WILL CONTINUE TO INCUR CLAIMS, LIABILITIES AND EXPENSES WHICH WILL REDUCE THE AMOUNT AVAILABLE FOR DISTRIBUTION TO STOCKHOLDERS.

Claims, liabilities and expenses from operations (such as operating costs, salaries, income taxes, payroll and local taxes, legal and accounting fees and miscellaneous office expenses) will continue to be incurred as we wind down. These expenses will reduce the amount of assets available for ultimate distribution to stockholders. If available cash and amounts received on the sale of non-cash assets are not adequate to provide for our obligations, liabilities, expenses and claims, we may not be able to distribute meaningful cash, or any cash at all, to our stockholders.

DISTRIBUTION OF ASSETS, IF ANY, TO OUR STOCKHOLDERS COULD BE DELAYED.

Our Board of Directors has not established a firm timetable for distributions to our stockholders, and we are currently unable to predict the precise timing of any distribution, if any, pursuant to our wind down. The timing of distribution, if any, will depend on and could be delayed by, among other things, the timing of sales of our non-cash assets, claim settlements with creditors and the amounts paid out under warranty claims. Additionally, a creditor could seek an injunction against the making of distributions to our stockholders on the ground that the amounts to be distributed were needed to provide for the payment of our liabilities and expenses. Additionally, we could seek protection from creditors under the federal bankruptcy code. Any action of this type could delay or substantially diminish, or eliminate, the amount available for distribution to our stockholders.

14


--------------------------------------------------------------------------------

Table of Contents

IF WE FAIL TO CREATE AN ADEQUATE CONTINGENCY RESERVE FOR PAYMENT OF OUR EXPENSES AND LIABILITIES, OUR STOCKHOLDERS COULD BE HELD LIABLE FOR PAYMENT TO OUR CREDITORS OF EACH SUCH STOCKHOLDER’S PRO RATA SHARE OF AMOUNTS OWED TO THE CREDITORS IN EXCESS OF THE CONTINGENCY RESERVE, UP TO THE AMOUNT ACTUALLY DISTRIBUTED TO SUCH STOCKHOLDER.

If the Plan is ratified and approved by the stockholders, we will file a Certificate of Dissolution with the State of Delaware dissolving the Company. Pursuant to the Delaware General Corporation law, we will continue to exist for three years after the dissolution becomes effective or for such longer period as the Delaware Court of Chancery shall direct, for the purpose of prosecuting and defending suits against us and enabling us gradually to close our business, to dispose of our property, to discharge our liabilities and to distribute to our stockholders any remaining assets. Under the Delaware General Corporation Law, in the event we fail to create an adequate contingency reserve for payment of our expenses and liabilities during this three-year period, each stockholder could be held liable for payment to our creditors of such stockholder’s pro rata share of amounts owed to creditors in excess of the contingency reserve, up to the amount actually distributed to such stockholder.

However, the liability of any stockholder would be limited to the amounts previously received by such stockholder from us (and from any liquidating trust or trusts) in the dissolution. Accordingly, in such event a stockholder could be required to return all distributions previously made to such stockholder. In such event, a stockholder could receive nothing from us under the Plan. Moreover, in the event a stockholder has paid taxes on amounts previously received, a repayment of all or a portion of such amount could result in a stockholder incurring a net tax cost if the stockholder’s repayment of an amount previously distributed does not cause a commensurate reduction in taxes payable. There can be no assurance that the contingency reserve established by us will be adequate to cover any expenses and liabilities.

15


--------------------------------------------------------------------------------

Table of Contents

OUR STOCK TRANSFER BOOKS WILL CLOSE ON THE DATE WE FILE THE CERTIFICATE OF DISSOLUTION WITH THE DELAWARE SECRETARY OF STATE, AFTER WHI

[Flickus]

@Viva-los-Tioz:
Hi, ich kann zwar Englisch, aber dieser Bericht ist mit Fachausdrücken voll, was sagt er aus, kannst Du`s --wenn
möglich -- so mit 2-3 Sätzen im Groben sagen.
Können wir noch was tun außer abwarten??Denn Verkaufen brauch ich nu nicht mehr, hatte auch vorsichtshalber mal keine Stop gesetzt:-(
Haften wir Aktionäre für die Schulden eigentlich mit??
Oder bischen zocken??
Fragen über Fragen
Gruß Flickus

[Big Charly]

Medical Solutions
Audiologie


Erlangen, 15. November 2002



Siemens sichert Nachsorge der europäischen Patienten mit dem implantier-baren Hörsystem Vibrant Soundbridge auch nach Produktionseinstellung des Gerätes durch den Hersteller Symphonix

Auch nach der Produktionseinstellung des implantierbaren Hörsystems Vibrant Soundbridge durch den US-amerikanischen Hersteller Symphonix Devices wird Siemens weiterhin die Nachsorge der betroffenen Patienten sichern. Aufgrund nicht gewinnbringender Vermarktung des Gerätes auf dem amerikanischen Markt gab Symphonix gestern bekannt, das Hörsystem nicht weiter produzieren zu kön-nen. Die Siemens Audiologische Technik GmbH (SAT) ist seit Juni 2000 Ver-triebspartner von Symphonix in Europa. Zur Geschäftsaufgabe von Symphonix stellte Dr. Roger Radke, Sprecher der Geschäftsführung von SAT, klar: „Das Wohl der Patienten steht jetzt im Vordergrund. Siemens wird seine langjährige Kompetenz auf diesem Gebiet auch nach der Geschäftsaufgabe des Herstellers den betroffenen Kliniken und Hörgeräteakustikern in Europa zur Verfügung stel-len und damit für eine optimale Betreuung der Patienten sorgen.“

Die Vibrant Soundbridge wurde in 13 europäischen Ländern an insgesamt 97 Kliniken implantiert. Die klinische Erfahrung zeigt, dass Patienten mit dem implan-tierbaren Hörsystem Vibrant Soundbridge langfristig sicher und effektiv versorgt sind.

Siemens Medical Solutions (Med) ist weltweit einer der größten Anbieter im Gesundheitswesen. Der Bereich steht für innovative Produkte, Dienstleistungen und Komplettlösungen. Abgedeckt wird das gesamte Spektrum über bildgebende Systeme für Diagnose und Therapie, die Elektro-medizin und die Audiologie bis hin zu IT-Lösungen, die Arbeitsabläufe in Kliniken und Praxen op-timieren und zu einer höheren Effizienz führen. Zum Angebot gehört auch die Übernahme des Datenmanagements beim Kunden als Application Service Provider bis hin zu an spezifischen Krankheitsbildern ausgerichtetem Prozessmanagement in der Vorsorge, Heilung und Pflege. Med beschäftigt weltweit rund 31 000 Mitarbeiter. Im Geschäftsjahr 2002 (30. September) erzielte Med nach vorläufiger Rechnung einen Umsatz von 7,6 Mrd. € sowie einen Auftragseingang von 8,4 Mrd. €. Das EBIT betrug 1 Mrd. €. Weitere Informationen unter: http://www.siemensmedical.com.

Hallo, Symphonixaktionäre
das ist wohl ein Schlag, bin bei Höcstkurs eingestiegen und habe, wie wir alle, an dieses Produkt geglaubt.
Was glaubt Ihr alle,
soll man zocken versuchen verbilligen und an Nasdaq verkaufen
Big Charly

[Flickus]

Hallo Leute, hat einer noch was neues, vielleicht doch noch einen Verkauf oder ne Übernahme, das der Kurs eventuell noch ein bischen hochkommt. Die können doch nicht einfach nur dicht machen und all die Aktionärskohle ist denen am Arsch.
@Viva-los-Tioz:
laß mich jetzt nicht allein :-))

Wer hat denn noch Shares von Euch? Bei mir ist jetzt ein schöner VW Polo wech, beziehungsweise, das Geld für ihn hat jetzt ein anderer.

[Viva-los-Tioz]

Hallo Flickus,

bin noch dabei da es jetzt sowieso egal ist zu verkaufen.

Vielleicht passiert ja noch ein Wunder mit Smpx,wenn nicht dann ist die Kohle eben weg.


Gruß
Viva

[HAIRMAN2002]

Könnten sehr bald bis 30 US-cents laufen - heute 9,5Mill. Shares gehandelt.

Es soll eventuell mit SIEMENS zum Deal kommen...drinbleiben!

Gruss vom
Hairman

[HAIRMAN2002]

SYMPHONIX DEVICES WKN 912376

Liquidation wird wohl vermieden - SIEMENS will das Unternehmen, mit dem man erfolgreich zusammenarbeitet, u.U. doch
ÜBERNEHMEN!!!

Gestern wurden 9,5Mill. Shares gehandelt, bei einem Plus von 80%, nachbörslich weiter rauf!!!

Das Gap verläuft bei 0,30$ - noch jede Menge Potiental!

KAUFEN!!!

Gruss vom
Hairman

[*Burna*]

viva mensch du hast ja aber auch überall deine finger drin

burna

[alanthegreenhorn]

guten morgen liebe symphonix gemeinde

würde mich mal interessieren wer da von euch in frankfurt mit 20000 Stücken zu 0,13 zugeschlagen hat und warum?

besten dank!!!!!!!

[jojobada]

ich wollte mein Glück auch mal versuchen zu
in der Regel halbieren sich meine Werte sofort nach dem Kauf
deswegen habe ich erst eine Schüppe voll genommen und den Rest später
ich hoffe doch das es gut geht sonst kann ich mein Investment für Jahre wieder vergessen
wei ich so ein Glückspilz bin


mfg jojo

[micky1]

ich weiss nicht, irgendwie erinnert mich das an Turbodyne

aber ihr seid wohl zu jung um die noch zu kenne

micky

[Flickus]

Hallo Syphoniker,
nichts neues? Einer ne Idee, wie`s weitergeht?
@ Viva-loz-Tioz
Du auch nix neues??
cheers&beers
flickus

[Flickus]

Hallo Syphoniker,
nichts neues? Einer ne Idee, wie`s weitergeht?
@ Viva-loz-Tioz
Du auch nix neues??
cheers&beers
flickus

[Flickus]

Hallo Syphoniker,
nichts neues? Einer ne Idee, wie`s weitergeht?
@ Viva-loz-Tioz
Du auch nix neues??
cheers&beers
Flickus

[Flickus]

Hallo Syphoniker,
nichts neues? Einer ne Idee, wie`s weitergeht?
@ Viva-loz-Tioz
Du auch nix neues??
cheers&beers
Flickus

[Flickus]

Hallo Symphoniker,
nichts neues? Einer ne Idee, wie`s weitergeht?
@ Viva-loz-Tioz
Du auch nix neues??
cheers&beers
Flickus

[Flickus]

Huch,
einmal hätte ja auch gereicht :-)) Kompjutazeitalter

[Viva-los-Tioz]

Hallo Flickus,

ich war bis heute Morgen im Krankenhaus so das ich mich erstmal wieder einfinden muß.

Gruß
Viva

[Viva-los-Tioz]

@alle

Was sagt man dazu,drüben steht der Kurs bei 0,14cent

[Flickus]

@Viva-los-Tioz:
Dann erstmal willkommen back in the realworld :-))
Hab ausgerechnet, noch 15 x plus 70% und ich hör auf mit meinem Job *lach*
Ich vermute, da gibts gute News aus dem Hause Siemens oder ein anderer Investor ist da, ich glaube aber mehr an Siemens.
Männo, wollte eigentlich nachkaufen, aber leider "Angst essen Seele auf", ist die Frage, ob die auch mal wieder in Richtung 1 Euro oder sogar mehr gehen können oder ob wir bald Siemensaktionäre sind??
Was meinst Du?
PS:
Gute Genesung, hattest doch hoffentlich nicht wegen Deinen shares nen Kreislaufzusammenbruch :-))
Grüße&nice weekend
Flickus

[Viva-los-Tioz]

@Flickus

Du hast Post

Gruß
Viva

[Flickus]

@Viva-los-Tioz
Du jetzt auch :-))
Gruß Flickus

[DOXA DRAMA]

sieht gut aus,heute 0,16$ +45%

[Viva-los-Tioz]

@alle

Was glaubt Ihr,sind die Kursgewinne in den letzten Tagen auf Zocker zurück zu führen oder was passiert da gerade mit Smpx?


Gruß
Viva

[mr.Seefeld]

Morgen früh bei 0,11Cent.

[Viva-los-Tioz]

Also doch nur die Zocker!

Dec 2 2002 StockPickReport.Com Announces Stock Ratings: New Ratings on Riverstone Network, Symphonix Devices, Dupont, Aquila, Lehman Brothers